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ABSTRACT OF THE DISSERTATION
THE ROLE OF ENDOTHELIN 3 IN MELANOMA PROGRESSION AND
METASTASIS
by
Nikeisha Latoya Chin
Florida International University, 2015
Miami, Florida
Professor Lidia Kos, Major Professor
Endothelin receptor b (Ednrb) and its ligand Endothelin 3 (Edn3) have been
implicated in melanoma. Several studies have shown an upregulation of EDNRB
and EDN3 at both the protein and mRNA levels, as melanoma becomes more
aggressive. This study investigated the putative role played by Edn3 overexpression in melanoma progression and angiogenesis in vivo. We crossed
Tg(Grm1)Epv transgenic mice that aberrantly express metabotropic glutamate
receptor1 under the Dopachrome tautomerase promoter, leading to spontaneous
melanocytic lesions in the ears and tails that do not metastasize, with transgenics
that overexpress Edn3 under the Keratin 5 promoter (K5-Edn3) or overexpress
Ednrb in melanocytes (Tg(Ednrb)1Lk). In both the Tg(Grm1)Epv/K5-Edn3 and
Tg(Grm1)Epv/Tg(Ednrb)1Lk mice, tumors appeared earlier and grew significantly
larger and faster when compared to Tg(Grm1)Epv mice. Approximately eightyone percent of Tg(Grm1)Epv/ K5-Edn3 mice and 76% of
Tg(Grm1)Epv/Tg(Ednrb)1Lk mice had pigmented lesions in distant organs such
as the lung and brain. Real-Time PCR analysis showed higher expression levels

viii

of genes involved in cell-cell and cell-matrix interactions and angiogenesis in
lesions of Tg(Grm1)Epv/K5-Edn3 when compared to controls. Considering the
rapid tumor growth rate of in the Tg(Grm1)Epv/K5-Edn3 mice, differences in the
angiogenic response compared to control mice were investigated.
Immunofluorescence analysis with the endothelial cell marker CD31 showed that
there were more endothelial cells per tumor area in the Tg(Grm1)Epv/K5-Edn3
mice than the controls. Proteome analysis showed that the Dct-Grm1/K5-Edn3
mice had significant increases in other angiogenic related genes such as Angiogenin,
CXCL 16 and Endoglin, when compared to controls, while real time PCR analysis of
tail tumors also showed higher expression levels of angiogenic related genes
such as Hif-1α. The results of this study showed that the EDNRB/EDN3 axis is
sufficient to alter the kinetics of melanocytic tumors’ progression, lead them to a
fully malignant state, and increase the tumor angiogenic response.
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CHAPTER I
INTRODUCTION

1

I.
1.1.

INTRODUCTION
The Skin

It is not unforeseen that skin cancer is the most prevalent of all human cancers,
affecting approximately 1 million people in the United States each year, taking
into consideration that the skin is the largest organ of the body. The skin forms
the primary protective external barrier against foreign invaders and ultraviolet
radiation (UV). There are three primary layers of the skin, the epidermis, the
dermis with the basement membrane situated in between both, and the
hypodermis or subcutis which is the deepest layer. Skin cancers develop
primarily in the cells of the epidermis.
The epidermis is the outermost layer and thus the first level of protection.
In the human skin this layer is ~0.1-0.2mm thick and consists of 5 separate
strata. From outermost to innermost the sections are the stratum corneum, the
stratum lucidum, the stratum granulosum, the stratum spinosum and the stratum
basale. The four major types of cells found in the epidermal layer are
keratinocytes, melanocytes, Merkel cells and Langerhans cells. Langerhans are
antigen presenting immune cells found mainly in the stratum spinosum, while
Merkel cells are receptor cells found in the stratum basal and are thought to be
involved in somatosensory effects.
Keratinocytes are the most abundant type of cell in the epidermis. These
cells begin as germinal cells in the stratum basal. Each of the other strata of the
epidermis contain different maturation stages of the keratinocytes as they
undergo cornification. Cornification is the process whereby these cells produce
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the fibrous structural protein, keratin. As the cells accumulate keratin, the
organelles and nuclei are lost, finally generating a protective layer of dead cells
filled with keratin in the stratum corneum layer.
Melanocytes are the dendritic pigment producing cells of the body that
are responsible for the actual skin color phenotype in human beings 1.
Embedded in the epidermal-dermal junction of the skin, melanocytes execute a
complex process of synthesizing and storing the pigment melanin in lysosome
related organelles called melanosomes 2. Melanocytes produce two types of
pigment, eumelanin which is brownish-black in color and pheomelanin which is reddishyellow.
Melanosomes travel to the dendritic tips of the melanocytes where they
are then released into the intercellular space, allowing endocytosis and
phagocytosis of the melanosomes by the keratinocytes 2–5. The melanin forms a
cap over the nuclei of the keratinocytes, and protects the DNA from harmful UV
by absorbing UVA (320-400nm) and UVB (260-320nm) rays 4,5. One melanocyte
distributes melanosomes to approximately 36 keratinocytes making up an
‘epidermal melanin unit’ 4. This ratio of melanocytes to keratinocytes remains
stable. Although keratinocytes have a high rate of growth and proliferation in the skin,
melanocyte proliferation is strictly controlled by the keratinocytes. When melanocytes
were co cultured with undifferentiated keratinocytes, the melanocytes were nonproliferative, however when the melanocytes were cultured with differentiated
keratinocytes melanocytes proliferated at rates matching the keratinocytes and developed
multiple dendrites 6. During the few times melanocytes need to divide, the melanocyte
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has to first detach from the basement membrane and keratinocytes and retract their
dendrites before being able to proliferate. Afterwards, the melanocytes must adhere once
again to the matrix and establish reconnection with the keratinocytes 4. Cross-talk
between melanocytes and keratinocytes is multifaceted involving a number of
keratinocyte derived factors such as hepatocyte growth factor (HGF), basic fibroblast
growth factor (bFGF), prostaglandins and steel factor/KIT ligand 7,8. This communication
is very important in maintaining proper melanin production, and protection from UV
damage. Dysregulation of any of these mechanisms can lead to various skin cancers, the
most aggressive and terminal one being melanoma resulting from transformation of
melanocytes.
1.2.

Melanoma Skin Cancer

1.2.1. Statistics and Stages
Melanoma comprises less than 2% of all skin cancer cases, however it is
responsible for most of the deaths caused by skin cancer. There have been
reports that melanoma incidence has been considerably increasing over the past
thirty years 9,10. The American Cancer Society estimated that in 2015
approximately 74,000 individuals will be diagnosed with melanoma, about 43,000
of those diagnosed will be in men and 31,000 of those will be women. Although
the risk of melanoma increases with age, it is one of the most common cancers
seen in young adults 11. There are several common elements that increase the
lifetime risk of an individual being diagnosed with melanoma, the first, possessing
acquired atypical moles/dysplastic nevi. Atypical moles are pigmented lesions
that are usually benign, however if the moles change shape, color or size, they
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may be potential sites of melanoma 12,13. The second risk is known as ‘familial
atypical multiple mole melanoma syndrome (FAMMM). This condition is inherited
and is assessed when an individual has a number of dysplastic nevi and a least
one family member that has had melanoma 14,15. Hereditary melanoma accounts
for about 10% of melanoma cases 15. The third high risk element is ‘phototype’,
an individual’s skin color and proneness to tan 16. Caucasians are more than 20
times more likely to get melanoma than blacks 9,17. Furthermore individuals with
mutations in the melanocortin 1 receptor (MC1R) with very fair skin, red hair and
light eyes are most at risk for acquiring melanoma18. The MC1R receptor is a
seven transmembrane G-protein coupled receptor found on the plasma
membrane of melanocytes. Stimulation of MC1R by its ligand α-melanocyte
stimulating hormone (α-MSH) or other agonist adrenocorticotropic hormone
(ACTH) by keratinocytes in response to UV, induces adenyl cyclase to produce
cyclic AMP (cAMP) 19,20. The increase in cAMP levels in turn phosphorylates and
activates the cAMP responsive element binding protein (CREB) family of
transcription factors. One important target of CREB is microphthalmia
transcription factor (MITF), a basic helix-loop-helix leucine zipper (b-HLH-Zip)
transcription regulator for genes encoding enzymes involved in melanin synthesis
such as tyrosinase, Dopachrome tautomerase (DCT) and tyrosinase-related
protein-1 (TRP-1) 20–24.
The MC1R gene is a major gene responsible for pigmentation phenotype
25

. There are a number of polymorphisms and allelic variants of the gene leading

to differences in skin color and phototype in humans 26,27. The MC1R variants
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R151C, R160W and D294H are linked to the ‘red hair color phenotype’ (RHC) 28–
30

. These single amino acid substitutions results in mutants unable to bind or

activate adenyl cyclase which results in an increase in pheomelanin synthesis,
which is more cytotoxic and less protective from irradiation than eumelanin 27–30.
The first stage of cutaneous melanoma is the common acquired and
congenital nevi. This stage does not normally show any dysplastic changes 31,32.
The second stage is the formation of dysplastic nevi 31–33. Dysplastic nevi have
progressed to acquiring structural and architectural atypia. The radial growth
phase (RGP) is the first malignant stage. At this stage the abnormal melanocytes
start to spread laterally, but still remain close to the epidermis 31–34. Although the
tumor cells are locally invasive, they are not yet undergoing rapid growth. The
RGP cells are still controlled by the exogenous growth factors of the
keratinocytes. In the vertical growth phase (VGP) the melanoma cells are highly
tumorigenic and clinically dangerous 31–34. The tumor cells have gained
metastatic potential and are now found in the basement membrane. The cells
continue to invade both the upper and lower layer of the epidermis and dermis.
The tumor cells in the area mostly form clusters of cells, with few cells breaking
off and forming isolated regions. This stage of melanoma usually has poor
clinical outcome, as the VGP melanomas increase their vascularization enabling
them for the fifth stage 31–34. At the metastasis stage the VGP cells are now
completely free from keratinocyte signals, and have formed new interactions with
other cells such as fibroblasts. The VGP’s now proliferate rapidly, overcoming
anchorage constraints. The VGP’s are able to disperse to other organs in the
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body 31–34. It is important to note that these steps in melanomagenesis do not
always occur sequentially. Malignancy may occur from melanocytes that do not
go through the nevus stage 32. Melanomagenesis is triggered by a combination of
key genetic factors, UV- exposure and the tumor microenvironment.
1.2.2. Genetic Factors of Melanoma
The cyclin dependent kinase inhibitor 2A (CDKN2A) gene located on the
9p21 locus has been generally accepted as a familial melanoma susceptibility
gene 33,35–37. Several linkage and meta- analysis studies have identified loss of
heterozygosity and germline mutations of CDKN2A in families with two or more
individuals that were diagnosed with melanoma 36,38,39. Approximately 25-40% of
melanoma prone families exhibit INK4A mutations, however ~0.2-2% of
individuals with sporadic melanoma have also been found to possess mutations
in the gene 40. The CDKN2A gene encodes two tumor suppressor proteins,
Inhibitor of cyclin dependent kinase 4 (INK4A/p16INK4A) and the Alternative
reading frame product (ARF/p14ARF) (p19ARF in mice) using two different
promoters, 1α and 1β for INK4A and ARF, respectively, as well as different first
exons. The two alternative transcripts share exons 2 and 3, however the open
reading frames in exon 2 are distinct for INK4A and ARF resulting in the
translation of two proteins with no common amino acid homology 41–43.
The protein INK4A inhibits cyclin dependent kinase 4, a regulator of cell
cycle progression utilizing retinoblastoma protein (RB). RB is a tumor suppressor
protein that binds to and obstructs transcription factors of the E2F family.
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The E2F proteins along with their dimerization partners (DP) drive the cell
cycle into the S phase. When RB binds to E2F forming a RB-E2F/DP complex, it
inhibits excessive cell growth by resting the cell cycle in the G1 phase. When cell
division needs to proceed, RB is hyper-phosphorylated by CDK4 which renders
RB unable to bind to E2F and thus allowing the cell cycle to progress form G1 to
the S phase. The INK4A gene is therefore a negative regulator of cell cycle
progression as it blocks CDK4 from phosphorylating RB to induce cell division.
The importance of the INK4A/CDK4/RB- pathway is further evidenced by
the finding of germline mutations for CDK4 in familial melanoma 44–47. Alterations
of CDK4 are attributed to Arg24Cys or Arg24His mutations that prevent
inactivation of CDK4 by INK4A 48. The CDK4 mutations are not paired with
somatic INK4a activation, but both mutations can give rise to melanomas with
similar incidence and progression mutually exclusive of each other 49. Sotillo et
al. (2001) reported that mice with a targeted ‘knock in’ mutation of Cdk4
developed melanomas after exposure to carcinogens 50.
A number of familial melanoma cases 51, metastatic cell lines52, as well as
germline and sporadic deletions or mutations of 1β in the ARF coding sequence
have been presented. These mutations of p14ARF are exclusive from INK4A
mutations, suggesting an independent role for p14ARF in melanomagenesis.
Although in mice Ink4a deficiency results in the development of tumors 53, when
p14ARF haploinsufficiency was combined, the tumor phenotype was
heightened 53,54.
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In response to an increase in aberrant mitogenic and oncogenic signals
p14ARF acts as an important tumor suppressor 55. Overexpression of mitogens
MYC and RAS stimulate the increase in p14ARF transcription and its accumulation
in the nucleus where p14ARF binds to and inhibits MDM2, a ubiquitin ligase of
p53 56,57. Binding of p14ARF to MDM2 allows p53 to trigger cell growth arrest and
apoptosis 57,58. Loss of p14ARF function results in an increase in MDM2 and a
concomitant loss of p53 mediated cell cycle control, resulting in cancer
progression. The p14ARF protein can also inhibit proliferation independently of
p53 by binding to nucleophosmin/B23, a ribosomal chaperone protein that
prevents rRNA processing 59. Triple ‘knockout’ mutant mice (TKO) nullizygous for
rf p53 and Mdm2 acquired tumors significantly more than mice lacking only p53
or p53 and Mdm2. When ARF was restored in TKO embryo fibroblasts, Weber
and colleagues found that ARF could arrest the cell cycle in the absence of
MDM2, thus confirming that ARF can act through other mechanisms for cell cycle
control 60.
Although mutations within the coding region of p53 (Tp53) are often
associated with most cancers, often p53 is not modified directly in human and
murine melanomas. The mutation and subsequent targeted loss of p14ARF in
melanoma may be the means for the p53 pathway to be disrupted.
Recently a link between the CDNK2A locus and MC1R has been
established. A study on Australian families with individuals diagnosed with
melanoma with CDKN2A mutations by Box and colleagues (2001) discovered
that if a single MC1R polymorphism was present, the raw penetrance of the
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CDKN2A mutation would significantly increase as well as earlier onset 61. van der
Velden and colleagues (2001) also studied Dutch families with FAMM, and
described that the number of MC1R mutations in the individuals with CDNK2A
mutations increased melanoma penetrance 62. The MC1R mutations can
therefore act as modifiers of melanoma susceptibility in individuals with CDKN2A
mutations.
Over activation of the receptor tyrosine kinase (RTK) pathway, especially
that involving one of its most important mediators, the mitogen activated protein
kinase (MAPK) pathway is identified in a number of cancers including melanoma
63

. Receptor tyrosine kinase ligand binding activates the RAS family of GTPases

(NRAS, HRAS, and KRAS). The protein RAS then activates the Raf family of
serine threonine specific protein kinases (BRAF, ARAF and c-RAF1) which
regulates the MAPK pathway to phosphorylate and activate extracellular signal
regulated kinases 1 and 2 (ERK1 and ERK2) to promote transcription of genes
participating in cell growth, differentiation, migration and senescence 64,65. The
majority of the BRAF constitutively active proto oncogene mutations, have been
identified as a point mutation (T1799A), a T-A transversion (converts valine to
glutamic acid) that encodes BRAFV600E 66–71. Davies and colleagues (2002)
genome wide cancer screening discovered activating BRAF mutations in
approximately 60% of somatic melanoma cases 68. Poynter and colleagues
(2006) found the highest incidence of BRAF mutations in nevi (82%), followed by
invasive melanomas (29%) with the least being in in-situ melanoma (5.6%) 72.
Mutation analysis on melanoma and nevi samples by Pollock and colleagues
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(2003) as well as sequence analysis by Kumar and colleagues (2004) also
detected BRAF mutations occurring mostly in benign or dysplastic nevi, thus
suggesting that BRAF may be important in early transformation of melanocytes
but other mechanisms may be necessary for complete melanoma
progression 73,74. Supporting this view are findings from Patton and colleagues
(2005) that created a transgenic BRAFV600E mutant expressing zebrafish model.
The fish acquired patches of ectopic melanocytes which only became invasive
melanomas after the activated BRAFV600E was paired with p53 deficiency 75.
The BRAFV600E mutations occurrence in cutaneous melanomas have been
correlated with UV exposure. Studies by Maldonado and colleagues (2003) and
Curtin and colleagues (2005) examined cutaneous melanomas from different
groups with different degrees of exposure to UV for alterations in BRAF. Both
groups found that BRAF mutations were more common in melanomas that arose
from skin exposed to intermittent high intensity UV exposure with very few BRAF
mutations associated with melanomas from limited sun exposure such as
mucosal melanomas and ones on the palms or soles of feet 66,76. Although this
would suggest a causal link for BRAF mutations by UV, the relationship is not as
simple, as both groups also found that BRAF mutations were also rare in
melanomas arising from chronic exposure to UV 66,76. It has been suggested that
BRAF mutations may be a result of cytotoxic, oxidizing or inflammatory response
associated with intense sunlight exposure as opposed to being directly induced
by UV 77.
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Unlike BRAF mutations in melanoma NRAS mutations have been shown
to manifest as a result of UV exposure. van Elsas and colleagues (1996)
detected NRAS mutations in 26% of paraffin embedded DNA from melanoma
samples exposed to chronic sunlight, with no NRAS mutations found in sun
protected melanomas. The NRAS mutations occurred more frequently in
individuals from the high sun exposed area, Australia, than individuals from North
or Central Europe 78. The NRAS point mutations are rarely found in dysplastic
nevi, but are found in most stages of melanoma including congenital nevi,
primary melanomas and metastatic melanoma indicating a progressive type role
for NRAS in melanomagenesis 78–81. The HRAS and KRAS mutations are seldom
seen in melanoma 69,72,78,81. In transgenic mice Hras mutations on an Ink4a
deficient background developed non metastatic melanomas, however Nras
mutations on a Ink4a deficient background led to those transgenic mice
developing spontaneous cutaneous melanomas with high penetrance 82,83. More
studies are needed to fully understand the importance of RAS and RAF signaling
in melanoma.
Hyperactivity of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway is a
common event in melanomagensis. Dai and colleagues (2005) examining
phospho-Akt (p-Akt; Ser-473) in melanocytic lesions at different stages of
progression found phospho-Akt expression increased as melanocytic lesions
became more aggressive. Patient survival was also inversely correlated to pAKt
expression 84. The (PI3K)-AKT pathway can be activated by RTK’s, RAS
proteins, integrins or G-protein coupled receptors. Activation leads to production
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of phosphatidylinositol (3,4,5) trisphosphates (PIP3), which serve as docking
sites for other proteins with pleckstrin-homology (PH) domains to phosphorylate
the chief effector of the PI3K pathway, protein kinase B (PKB) also known as
AKT 85–87. AKT phosphorylates targets that can initiate or inhibit cell growth,
proliferation, survival and migration 85,88,89,89. Loss of heterozygosity (LOH) or
mutations of the tumor suppressor phosphate and tensin homolog (PTEN) is
perhaps the most studied regulator of PIP3 in melanoma 84,89–92. The protein
PTEN acts as a negative regulator of the PIP3 pathway, thus it is often found
mutated in a number of cancers 86,88,90,91. Expression analysis studies show LOH
of the PTEN and MYC antagonist MXI1 locus 10q24 develops in about 50% of
sporadic melanomas 88,92–95. Tsao and colleagues (2004) using mutated cell lines
demonstrated BRAF activated mutations in conjunction with PTEN loss
contribute to melanomagenesis 96. Dankort and colleagues (2009) corroborated
this phenomenon as their genetic altered mice expressing BrafV600E only
developed few metastatic melanoma lesions. However when the BrafV600E
mutation was combined with PTEN tumor suppressor gene silencing, the
melanomas became 100% penetrant with short latency and formed distant
metastatic lesions 67. The aggressive nature of melanomas is in part due to the
major mutations in these important tumor suppressor regulatory pathways. The
intricacy of these pathways makes finding very effective therapeutic regimes
targeting one of these players whether BRAF, PTEN, and others difficult.
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1.2.3. Environmental Factors of Melanoma
Ultraviolet radiation is the most well-known, although not fully
characterized, epidemiological factor for melanoma. Sunlight is divided into three
Ultraviolet light spectrum regions, UVA (320-400nm), UVB (290-320nm) and
UVC (200-290nm). Ultraviolet light in the C spectrum (UVC) is absorbed
completely by the ozone with no effect on terrestrial life, however both Ultraviolet
light in the A spectrum (UVA) and Ultraviolet light in the B (UVB) spectrum reach
Earth. Ultraviolet B rays are short wavelengths of light and are deemed to be
more carcinogenic as they are able to damage DNA in two different ways; either
by causing cyclobutane pyrimidine dimers (CPD’s) between adjacent thymine or
cytosine residues, or forming 6-pyrimidine-4-pyrimidone photoproducts (64PP).
These abnormalities create specific DNA mutations (C to T and CC to TT) 97–100.
Ultraviolet light in the A spectrum are longer wavelengths and although they
penetrate deeper into the skin than UVB rays, they mutate DNA indirectly, by
creating reactive oxygen species (ROS)101,102. The impact of UV mediated effects
working with genetic factors to induce melanoma was demonstrated by Kannan
and colleagues (2003) with murine melanoma mouse models with HRAS
activation and p19ARF loss. UV exposed Tyr-RAS p19ARF-/- mice developed more
melanocytic lesions with significantly shorter latency than Tyr-RAS p19ARF-/- mice
not exposed to UV. Approximately, 50% of the tumors in the Tyr-RAS p19ARF-/UV exposed mice also had amplification of cyclin dependent 6 (cdk6) implicating
a UV induced mutagenic effect involving the Rb pathway 103. Benaduce and
colleagues (2014) using mice that overexpress EDN3 under the Keratin 5
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promoter (K5-tTA; TRE-Edn3-lacZ) and XPA deficiency (Xpa-/- or Xpa+/-), showed
that a single neonatal dose of UV radiation, was sufficient to induce
melanomagenesis in mice constitutively over expressing End3, independent of
XPA deficiency 104. Xpa-/- mice over expressing EDN3 however, displayed
significantly higher penetrance and shorter tumor free survival than Xpa+/- mice
also over expressing EDN3 104. The K5-tTA; TRE-Edn3-lacZ mice have an
increased number of melanocytes in the epidermal-dermal junction which closely
resembles their placement in the human skin, unlike wild type mice whose
melanocytes are confined to the hair follicles. Therefore, it is still unknown
whether it is the presence of EDN3 in the microenvironement or the location of
the melanocytes that permits melanomagenesis upon UV exposure 104.
Melanin’s photo-protective mechanism involves the absorption of UV
photons that can otherwise be damaging to DNA, and the absorption of free
radical species generated as a result of UV exposure that can cause oxidative
stress and a cytotoxic environment 97. In addition to these mechanisms, UV
photons can directly cleave diacylglycerol (DAG) that activates the PKC pathway
to increase melanin synthesis.
Epidemiological data such as the pooled data analysis conducted by
Chang and colleagues (2009) find strong positive correlation between intense
intermittent UV exposure and the risk of developing melanoma 102,105–108. Berking
and colleagues (2001 and 2004) demonstrated this link using both ‘in vivo’ and
‘in vitro’ experiments that UVB radiation was necessary in addition to the
expression of growth factors basic Fibroblast Growth Factor ( bFGF), Kit ligand
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(SCF/KITL) and endothelin to fully transform melanocytes to metastatic
melanomas109 110. A meta-analysis by Whiteman and colleagues (2001) found
that sun exposure in children posed a greater risk for developing melanoma than
sun exposure in adulthood. Noonan and colleagues (2001) investigated the
correlation between the age of UV exposure and melanoma risk by creating
transgenic mice overexpressing Hepatocyte growth factor/scatter factor
(HGF/SF) under the metallothionein promoter 111. The HGF/SF ligand binds to
the receptor tyrosinse kinase MET receptor located on epithelial cells and
melanocytes 112–116. The HGF/SF protein is normally secreted by mesenchymal
cells in the skin where it promotes activation of mitogenic and morphogenic
signals for epithelial cells 112,114–118. In melanoma an autocrine signaling loop of
HGF/SF/Met promoting melanocyte proliferation and migration has been
identified in several studies 113,119. Upregulation of HGF/SF 112 and gain of
function mutations of Met had been linked to mutations in melanoma 118,120. The
HGF/SF transgenic mice possess melanocytes located in the epidermal-dermal
junction which more closely resembles the human skin phenotype as murine
melanocytes are normally confined to the hair follicles 111. Noonan and
colleagues (2001) found that a single neonatal dose of UV radiation, 30 fold
lower than that given in adult mice was sufficient to induce malignant melanomas
with short latency, thus providing evidence that avoiding UV exposure in
childhood is more important in preventing melanoma 111.
Some studies negate the positive relationship between childhood UV
exposure and melanoma 98. Pfahlberg and colleagues (2001) contradicted these
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findings as their study on several melanoma case studies in Europe compiled
with the history of sunburns in childhood and adulthood related to the cases, did
not find a similar gradient for melanoma risk between childhood sunburns and
those in adulthood. They did however find that more than five sunburns in life
doubled the melanoma risk despite them being childhood or adulthood 121,122.
Whiteman and his group (2001) reviewing both case type studies and ecological
studies that differed in this stance, stated that the way in which sun exposure
was measured led to the contradictory findings and that it appears that the
ecological type analysis studies were better and provided better quality evidence
to support the importance of the threat of childhood sunburns 123.
Another relationship between UV and melanoma that still needs to be
examined further is the speculation as to whether UVB or UVA differ in the effect
in causing DNA damage and inducing melanoma 124. There is some evidence to
suggest the importance of UVB as highly tumor initiating. Probing this
phenomena Fabo and colleagues (2004) irradiated HGF/SF transgenic mice with
either UVA, UVB or combined wavebands of radiation. The HGF/SF mice
irradiated with UVB acquired cutaneous malignant melanomas more readily and
efficiently than the HGF/SF transgenic mice exposed to just UVA 124. Human
newborn skin grafted onto 158Rag-1 transgenic mice also acquired melanocytic
lesions when exposed to chronic UVB radiation regardless of application of the
tumor initiating carcinogen DMBA 105.
The tanning response in humans is a complex combined effect stemming
from an increase in melanin production directed by melanocytes and mediated by
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keratinocytes, fibroblasts, neurons and mast cells in the immediate
environment97,125. These cells in response to UV stress increase the production
and release of various paracrine factors including bFGF, nerve growth factor
(NGF), α-MSH, and endothelin1 (Edn1). Other factors such as inflammatory
responses trigger receptors on the melanocyte to promote melanin synthesis,
dendricity as well as survival and proliferation of the cells 97,99,126. Thus the tumor
microenvironment (TME) is instrumental in inducing changes to transformed
melanocytes.
1.3.

Melanoma and the Tumor Microenvironment
The importance of the TME in melanoma progression becomes very clear,

considering that when melanoma cells are removed and placed into cultures,
they become increasingly vulnerable to targets or treatments. This behavior
differs remarkably from when these cells are in their TME in patients where they
are highly resistant to therapeutic regimens. The TME refers to the extracellular
matrix (ECM) and the cellular environment in which the tumor is situated. The
tumor milieu consists of, but not limited to, blood vessels, endothelial cells,
pericytes, immune cells, fibroblasts and the surrounding ECM. The tumor and
host environment are constantly communicating via a number of paracrine
signals to promote tumor escape from the host immune system, formation of new
vasculature and tumor heterogeneity which all facilitate growth, proliferation
survival and migration of tumorigenic cells. The tumor host environment is
primarily initiated by the tumorigenic cell, which then causes subsequent
mutations and modifications in nearby cell types to promote malignancy, a
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process known as co-opting. Cancer cells must circumvent restrictions and
environmental pressures in their environment, so that they can grow, survive,
and metastasize 127,128. Microenvironmental pressures include lack of oxygen or
nutrients, low pH, reactive oxygen species, and the inflammatory immune
response of the body, all of which contributes to metastasis initiation and an
increase in malignancy as the tumorigenic cells that can overcome these
challenges end up being selected for and contribute to the aggressive phenotype
127

. Melanomagenesis occurs not only because of an accumulation of genetic

alterations, but also because of a complex coordinated network of events
involving keratinocytes, fibroblasts, endothelial cells, pericytes and infiltrating
immunocytes.
1.3.1. Altered Cell-Cell Communication
The first critical event in melanomagenesis that transforms and shapes the
tumor microenvironment involves the severance of the symbiotic relationship
between keratinocytes and melanocytes. The separation allows melanocytes to
undergo an epithelial to mesenchymal transition (EMT). The EMT is the process
by which epithelial cells undergo morphological and molecular changes that
cause the cells to lose their polarity and cell-cell adhesion to gain migratory and
invasive plasticity associated with mesenchyme 127,129,130. The EMT normally
occurs at different stages of embryonic development, but is induced again by
cancer cells with the intention to surmount the constraints of the
microenvironment. To facilitate EMT various signaling pathways such as
PIP3,TGF-β/MAPK 131 and growth factors such as HGF/SF/ Met 132 are activated,
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as well as changes in the expression of cell-cell adhesion molecules (CAMs)
such as cadherins and integrins 128.
Keratinocyte governance over melanocytes is principally maintained by
contact-mediated regulatory mechanisms 133. Melanocytes adhere to, and
communicate with keratinocytes via Epithelial cadherin (E-cadherin) and
desmoglein, both of which are expressed on the cell membranes of keratinocytes
and melanocytes 134,135 . Co-culture experiments substantiate the control
keratinocytes have on melanocyte behavior and phenotype. In mono-culture
melanocytes are able to profusely proliferate, can exhibit bi-polar or tri-polar
morphology unlike their normal multi dendritic morphology and begin to express
proteases, growth factor receptors and melanoma associated antigens (MAA)
that are not expressed by melanocytes ‘in vivo’ 6,136,137. The protein E-cadherin is
expressed by melanocytes but not melanoma cells 134,138. Danen and colleagues
(1996) conducted flow cytometry experiments with normal and melanoma cell
lines and immunohistochemistry on frozen sections of melanoma lesions, found
E-cadherin expression only on normal melanocytes and naevus cells but none on
invasive metastatic melanoma cell lines 139. Thus transformed melanocytes have
to liberate themselves from keratinocyte-melanocyte adhesions by
downregulating E-cadherin during malignancy 134. Studies by Hsu and colleagues
(2000) showed that when E-cadherin expression was functionally restored to
melanoma cells by gene transfer techniques, a normal melanocyte phenotype
was re-established and invasion related antigens were downregulated 133,140,141.
Cytogenic and molecular analysis do not detect mutations, methylation or
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deletions in E-cadherin during melanomagenesis suggesting that downregulation
of E-cadherin may a result of the effects of growth factors 142,143. Because
HGF/SF/ MET signaling stimulates the proliferation and motility of melanocytes
144

and Met expression is found in melanoma 145, Li and colleagues (2001)

examined the effect of HGF/ MET on melanocyte transformation by inducing
autocrine activation of HGF using an HGF-expressing adenovirus. The autocrine
HGF signaling resulted in downregulation of both E-cadherin and desmoglein 1,
promoting proliferation and invasiveness of the tumorigenic cells 146. The
downregulation of E-cadherin therefore involves cross talk between melanoma
cells and HGF/ MET expressing cells such as fibroblasts. In addition to HGF,
studies also show that the Snail family of transcription factors that repress Ecadherin during embryonic EMT are also expressed and directly correlate to the
loss of E-cadherin in melanoma 143,147. Moreover, Schneider and colleagues
reported that UV-radiation of keratinocytes could induce paracrine release of
EDN1, which can reduce E-cadherin expression in melanocytes 148. In
melanomas, down regulation of E-cadherin is concurrent with an increase in the
mesenchymal protein neural cadherin (N-cadherin) 146,149.
The N-cadherin protein is normally expressed on endothelial, neuronal,
and muscle cells as well as fibroblasts and endothelial cells 150. The switch in
cadherin expression from E-cadherin to N-cadherin on melanoma cells alters the
binding partners of the transformed melanocytes from keratinocytes to
fibroblasts- and endothelial cells allowing the tumorigenic cells to now
communicate with these other cell types to prompt changes in the

21

microenvironment and incorporate and co-opt them as parts of the tumor, leading
to tumor heterogeneity 150. Wide global gene analysis techniques have
demonstrated that aggressive melanoma cell lines express a number of factors
that are affiliated with multiple cellular phenotypes such as fibroblasts,
endothelial cells, and immune cells 151–154. More importantly the transformed
melanocytes can now respond to mitogenic signals and proliferate without the
constraints of the keratinocytes and the upregulation of N-cadherin in melanoma
lesions confers a fibroblastic phenotype making the cells more motile and
invasive than normal melanocytes 149.
Additionally, transformed melanocytes display an upregulation of several
integrins such as α v β 3 along with the cadherin switch to change intercellular
signaling in the tumor microenvironment, as cadherins and integrins can regulate
RTK signaling 155–157, β-catenin/Wnt signaling 158 and activators of several
downstream targets such as small GTPases, Rho, Rac and Cdc42 8,150. These
genetic adaptations facilitate the survival, growth and migratory capabilities of
melanoma. α v β 3 Integrin expression in melanoma has also been linked to the
progression from RGP to VGP 159.
The EMT in melanoma not only permits tumor cell invasion and altered
cell communication partners by modifying cell-cell contacts, but also plays an
important role in remodeling the ECM making it conducive for invasion and
migration and creating what is coined ‘reactive stroma’ 160,161. The adaptation of
this stromal-cancer cell environment manifests even before the tumor is clearly
noticeable 127,160. The ‘reactive stroma’ consists of the tumor ‘in situ’, ECM and
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mesenchymal cells, fibroblasts, vascular networks and associated cells, nerves
and inflammatory cells resembling normal stroma when undergoing wound
healing 160–162.
During wound healing there is a period of ischemia where blood supply is
restricted accompanied by a shortage of oxygen and nutrients to the tissue,
edema, followed by an influx of immune cells, and then a period of blood vessel
growth and tissue repair 163,164. Tumor progression for most cancers undergo all
these phases of wound healing, generating the perception of cancers as ‘wounds
that do not heal’ 160,165.
Fibroblasts are the first main group of cells to accumulate at sites of
wound repair, where they present a scaffold for inflammatory and other cells that
mediate scar and tissue formation 160. The primary function of fibroblasts is aiding
in the formation of the basement membrane and synthesizing components of the
ECM, in which they are also embedded, such as collagen (I, III, V) and
fibronectin 166,167. Fibroblasts also secrete several important paracrine factors
such as Insulin-like growth factor 1 (IGF-1), transforming growth factor-β
(TGF-β), platelet derived growth factor (PDGF) and bFGF to maintain ECM
homeostasis and act in wound healing responses 159. After tumorigenic cells
undergo EMT, they can recruit and co-opt fibroblasts to secrete factors that only
potentiate the tumor microenvironment and promote tumor progression 159.
A specific population of fibroblasts has been identified as being directly
involved in cancer progression, they are known as cancer-associated-fibroblasts
(CAFs) 160,168. The CAFs are also termed ‘reactive stromal fibroblasts’ because
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they begin to express α-smooth-muscle actin similar to myofibroblasts.
Myofibroblasts are larger and more spindle-like in composition than regular
fibroblasts; they also typically divide faster and produce more ECM 159,169–171.
Tumors can directly secrete signals such as growth factors and chemokines to
dynamically recruit fibroblasts to the site of the tumor, while other fibroblasts may
arrive at the tumor in response to the reactive stroma that mimics a wound.
Melanomas can release a combination of bFGF, PDGF, and TGF-β signals to
stimulate and induct fibroblasts 172,173. When human melanoma cells (A2058)
were co-cultured with primary human fibroblasts (HS-68), the fibroblasts gene
expression was altered. The co-cultured fibroblasts began to significantly release
more CXCL1 and CXCL2 chemokines associated with melanoma growth and
migration. Meanwhile, the melanoma cells began to show a pro-inflammatory
response indicated by down regulation of Interleukin-11 and DNA binding
domain-1 in the cells 153. In a 3D co-culture model Flach and colleagues (2011)
found that melanoma spheroids could recruit and incorporate fibroblasts. The
presence of the melanoma cell soluble factors that recruited the fibroblasts also
increased the rate of wound closure as much as 38%, indicating an increase in
the secretion of fibroblast associated factors 171.
The CAFS in turn enhance the expression of the same signals as well as
release other factors such as IL-1, HGF, PDGF and Endothelin 3 (EDN3) to
promote melanoma growth, migratory capability and neovascularization 31,34,172.
Fibroblasts elicit different effects on melanoma progression depending on the
melanoma stage. Cornil and colleagues (1991) examined the effect dermal
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fibroblasts had on melanoma cells taken from different stages of melanoma
progression 174. When early metastatic incompetent melanoma cells taken from
RGP and VGP stages were co-cultured with fibroblasts, melanoma cell growth
was repressed. However when 9 out of 11 cell lines from metastatic phases were
co-cultured with fibroblasts, growth of the aggressive cell lines was stimulated 174.
It is speculated that the more aggressive tumor types may secrete factors that
can induce and recruit fibroblasts to then release paracrine factors in favor of
melanoma progression 159. Thus fibroblast activation may be induced by more
aggressive cell types within the tumor, moreover fibroblasts may aid in selection
and enhancement of the very aggressive melanoma cells 174.
Recently fibroblasts have been recognized as important components of
the body’s immune response at wounds or sites of inflammation 175. Fibroblasts
can secrete various cytokines and chemokines to initiate chronic inflammation
and regulate inflammatory infiltrates 160,176. When fibroblasts are co-opted by
melanoma cells, these inflammatory CAFs can maintain chronic inflammation
that characterizes the tumor microenvironment and aid in the tumor’s escape
from the hosts immune surveillance which is a major hallmark in tumor
progression 165,175,177.
1.3.2. Evading Immune Surveillance
Chronic inflammation in the TME creates tumor promoting effects as the
microenvironment is teeming with mediators of inflammation such as cytokines,
chemokines, growth factors, reactive oxygen species (ROS), nitrogen species
(NOS) and prostaglandins produced by the either the tumor or associated stroma
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cells 178179. The abnormal growth of a tumor summons immune effector cells to
the site of the tumor to deal with what is initially seen as a foreign invader,
however the TME has been altered so much that the anti-tumor functions of the
immune cells are downregulated, and instead tumor derived signals such as
TGF-β, Interleukin 8 (IL-8), bFGF and tumor necrosis factor- α (TNF-α)
successively recruit the inflammatory cells to support tumor progression 165.
Many of the inflammatory cells of both adaptive immunity such as Tlymphocytes, dendritic cells, and B cells and innate immunity including
macrophages, leukocytes and natural killer (NK) cells can even infiltrate the
tumor itself, favoring tumor survival and protection from subsequent immune
reactions outside of the TME 165. Another important group of immune cells found
in the TME are myeloid suppressor cells (MSCs) 180. Meyer and colleagues
(2011) using the ret transgenic melanoma mouse model showed high numbers of
myeloid suppressor cells infiltrating tumors and an increase in immune factors IL1β, granulocyte macrophage colony- stimulating factor-1 (GM-CSF), and
Interferon gamma (IFN-γ), in melanocytic lesions and lymph node metastases
correlating with tumor progression 177. Other studies demonstrated that,
dysplastic nevi and RGP have considerable numbers of lymphocyte infiltrates. It
is believed that melanoma cells can actively recruit lymphocytes by secreting
several chemoattractants namely IL-8, GM-CSF and monocyte chemoattractant
protein-1 (MCP-1) 31,181. Melanomas are able to further escape tumor
surveillance by promoting the release of immunosuppressants such as insulin
like growth factor-β (IGF-β) and IL-10 into the microenvironment 31.
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The recruitment of immune cells into the tumor microenvironment tricks
the host’s immune response into recognizing the tumor as ‘self’ rather than as a
dangerous group of cells. Melanoma is well known for its ability to escape the
host’s immune surveillance. The tumor escape from the immune system is one of
the features of the skin cancer that makes it very difficult to treat. The tumor
response mechanisms are complex and not yet fully characterized or
understood.
1.3.3. Inducing Neovascularization
Perhaps one of the most studied part of the TME response in tumor
progression is tumor angiogenesis. As the tumor grows and co-opts various cell
types into the tumor microenvironment and the tumor itself, oxygen and nutrients
become limiting, thus creating an increasingly hypoxic and unfavorable tumor
microenvironment 182. The tumor and the TME respond by triggering
angiogenesis, a mechanism described as the ‘tumor angiogenic switch’ 182–184.
Srivastava and colleagues (1988) found that the amount of staining for vessels
could indicate the probability of metastasis 185.
Tumor angiogenesis is the formation of new blood vessels from preexisting ones 186,187. The process is one of the most significant events of tumor
progression, as tumors cannot grow more than 2-3mm3 without vascularization
supplying the tumor with sufficient oxygen and nutrients as well as collecting
wastes from the tumor 182,187,188. Tumor angiogenesis follows several general
sequential steps. Angiogenesis begins with modifications and degradation of the
basement membrane by proteases, like matrix metalloproteinases (MMPs),
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permitting the detachment of pericytes which are contractile cells that cover
endothelial cells lining blood vessels 182,188,189. The detachment of pericytes
allows the directional migration of endothelial cells (ECs) into the interstitial
space towards angiogenic signals secreted by the tumor and TME. The ECs
proliferate and follow each other while forming attachments to each other,
subsequently forming a lumen and vessel branches, a process known as
sprouting 188,189. To end with, the basement membrane re-forms and pericytes
then re-attach to the newly formed vessels and blood flow begins 184,189,190.
Tumor blood vessel structure is uniquely different from those formed
during normal angiogenesis 188 189. The blood vessels of the tumor tend to be
irregularly shaped, deflated, very twisted and circuitous with some having dead
ends. Tumor blood vessels also lack definite organization into vein, arteries and
capillaries, moreover the vessels are often characterized as ‘leaky’ or
hemorrhagic, with poorly connected vessel walls, possibly due to the
overproduction of the vascular permeability factor, vascular endothelial growth
factor (VEGF). Blood flow is often irregular and slower in tumor vasculature than
in normal blood vessels 188 189. The abnormal properties of the tumor vessels
aids in preventing proper administration of drug therapies to tumors.
The ‘angiogenic switch’ encompasses a delicate balance between the
upregulation of positive angiogenic related factors such as VEGF family, bFGF,
HGF and IL-8 negative regulators of angiogenesis including thrombospondin-1
and angiostatin 183,184. The switch is prompted by tumor induction, hypoxic
conditions and oncogenic pathways 186. Tumor secreted autocrine growth factors
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stimulates tumor growth which then stimulates paracrine pro-angiogenic factors
that recruit stromal blood vessels 182,186. Transformed melanocytes, especially
those undergoing the VGP produce high amounts bFGF and VEGF both
important angiogenic factors. The vascular endothelial growth factor family
includes the key angiogenic regulator VEGF along with VEGFB, VEGFC, VEGFD
and placental growth factor which bind with various affinities to the VEGF
receptors Flt/VEGFR-1, Flk/KDR/VEGFR-2 and VEGFR-3. The VEGF receptors
are found primarily on endothelial cells, but can be located on macrophages,
bone marrow derived cells, vascular smooth muscle cells, hematopoietic cells
and on some malignant cells191–193. The VEGF protein acts as a potent mitogen
for endothelial cells (ECs) by activating phosphatidylinositol signal transduction
pathways and the MAPK pathway in endothelial cells. The Vascular endothelial
growth factor along with bFGF and other angiogenic factors, angiopoietins and
their tie receptors also mediate chemotaxis of ECs and are responsible for EC
survival, vessel sprouting and proper vessel formation 193–195. Melanoma
production of MMPs can release bFGF from the ECM, while cells in the TME
such as fibroblasts can produce VEGF along with melanoma cells 196.
Other angiogenic factors, placental growth factor (PIGF) 197and IL-8 198
which aid in EC recruitment and vessel formation have also been found to be
expressed by primary and metastatic melanomas to enhance tumor
angiogenesis 199. Secretion of IL-8 by endothelial cells in the TME can also
promote melanoma cell migration 199,200. Expression of urokinase plasminogen
activator and its receptor (uPA/uPAR) and MMPs which promote melanoma cell
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migration, invasion and metastasis can at the same time influence EC migration
and neovascularization 201,202.
Tumors can initially co-opt pre-existing vasculature until hypoxic
conditions trigger the secondary angiogenic response to create new
vasculature 203. Long diffusion distances in tumors creates chronic hypoxia and
necrotic regions in tumors, leading to the up regulation of angiogenic regulators
such as VEGF 186,188,195. Under normoxic conditions, oxygen sensing prolyl
hydroxylase domain proteins (PHD1-3) target the α-subunits of the hypoxic
regulator, Hif-1α, for degradation via ubiquitination 182. When conditions become
hypoxic however the α-subunit is stabilized and translocated to the nucleus
where it dimerizes with the β-subunit. The α/β complex then binds to hypoxia
response elements (HRE) in the promoter regions to activate the transcription of
angiogenic related genes such as VEGF, uPAR and MMP2 204,205. Hif-1α
expression has been confirmed in melanoma by immunohistochemical and
immunofluorescence of melanoma cells and biopsies and verified with western
blots and PCR 206–208. Increased expression of hypoxic inducible factors have
also been shown in metastatic melanomas when compared to benign nevi 209.
Treviño-Villarreal and colleagues (2011) demonstrated that cells in the TME like
stromal cells and pericytes expressed HIf-1α with the transformed
melanocytes 210.
Hypoxic conditions in the TME promote melanoma malignancy in two
ways; (1) stimulating tumor angiogenesis leading to increased vasculature in
which melanoma cells can enter into the circulatory and lymphatic system to
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invade and colonize distant organs and (2) provide an environment that selects
for the more aggressive cells that can withstand increased hypoxic conditions 182.
Liu and colleagues (2011) reported that hypoxia could up-regulate Snail1, a
mediator of decreased E-cadherin expression, thus aiding in EMT and melanoma
migration 211. Expression of Hif-1α is capable of actuating proto oncogenic
effects through pathways such as HGF/SF 212. Bedgoni and colleagues (2005)
found that constitutive PKB activity resulting from loss in PTEN could transform
melanocytes but only when exposed to hypoxic conditions. NRAS induced
melanocyte transformation was also favored by hypoxia 213.
In aggressive and highly metastatic melanomas an interesting group of
microcirculation patterns formed by the tumorigenic cells themselves has recently
been described as vasculogenic mimicry (VM) 214. The aggressive transformed
melanocytes showing great tumor plasticity, form cell lined channels with the
ECM to create their own tubular capillary-like network 152,214,215. Probst and
coworkers (2012) observing xenografts of human melanoma cell lines in nude
mice, found that some of the endothelial cells from microvessels formed in the
tumors were positive for human chromosome 17/Her-2, indicating that the
endothelial cells were melanoma in origin 216. The endothelial cell marker, CD31
and human Y chromosome ‘in situ’ and immunofluorescence labeling verified that
the melanoma cells acquired the vascular endothelial like morphology and could
contribute to creating neovascularization 216. The presence of VM in melanomas
is connected to poor prognosis and survival in patients 217,218. The exact
mechanism allowing VM is poorly understood. Vasculogenic mimicry modulating
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genes are generally categorized into pathways associated with not only vascular
signaling such as VE cadherin and VEGF but embryonic/stem cell signaling
including NOTCH and hypoxia signaling as well 219.
1.4.

Melanoma Heterogeneity and Malignancy
Tumor cell heterogeneity in the TME therefore not only defines the

presence of different cell types such as immune cells, pericytes etc. but
heterogeneity amongst the cancer cells themselves due to genetic and
epigenetic variations 220. Cancer tissues often consist of a sub-population of cells
that have adopted a ‘embryonic stem like’ phenotype which makes it easier for
them to adjust to the environment, and emit embryonic developmental factors to
alter the environment around them 221. The tumor stem cell (TSC) can self-renew
and transdifferentiate to adopt the roles of neighboring stromal cells 221–223. It was
originally thought that during melanoma progression, changes in genetic
expression of the tumor leading to TSCs or other melanoma cell phenotypes
were unidirectional. Recently, new studies are challenging that idea as it appears
that melanoma cells and its interaction with the TME allows for considerable
plasticity of the tumorigenic cells defined by different transcription signatures.
These interchangeable states alternate from a dominantly proliferative phenotype
to an invasive state and possible other intermediate stages in between 224.
Hoeck and coworkers (2012) used expression profiling of various
melanoma cell lines to identify transcription signatures for proliferative and
invasive melanoma cell states 224. Proliferative signatures include expression of
melanocytic related genes MITF, Tyrosinase (TYR) and Dopachrome
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Tautomerase (DCT), as well as neural crest factors associated with melanoblast
development such as SOX10 and Endothelin receptor b (EDNRB). The invasive
signature states included the up-regulation of Serpine1 and inhibin beta A
(INHBA) which are involved in TME modification 224. Hoeck and colleagues
(2012) then injected the DNA microarray characterized melanoma cell lines into
immunocompromised mice, after which immunohistochemistry was performed on
tumors to identify proliferative vs. invasive signatures. They showed that
melanoma cells could switch back and forth between different genetic signatures
as both proliferative and invasive cell types were found in the tumor despite what
the original seed cell signature was 224.
The phenotype switching of melanoma cells may facilitate the special
requirements of the cells in different melanoma states, from proliferative when
growth is necessary, to invasive, then back again to proliferative when at distant
metastatic sites. Phenotype switching may also explain why melanomas are
resistant to cancer regimens and often re-appear. Tumorigenic cells that are not
susceptible to chemotherapy may manipulate the TME to switch back to a
proliferative state and initiate tumor progression again. The key to revolutionizing
therapies for melanoma thus lies in understanding the dynamics of the tumor
microenvironment and targeting the important signals that maintain the malignant
cells.
The fact that malignant melanoma cells can alter their gene expression,
and subsequently the gene expression of neighboring cells, proves their ability to
adopt a ‘stem-cell likeness’, and become immortal, undifferentiated and invasive.
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The plasticity makes it easy for the cells to leave their origin and occupy other
regions. During melanomagenesis expression of genes involved with the
development of their early embryonic progenitors, melanoblasts, has been
observed. All melanocytes except for those found in the retina of the eye
originate from the neural crest (NC) during embryonic development. Neural crest
cells (NCC) are a transient and multipotent population of cells that are highly
migratory 225,226. The neural crest cells develop from the dorsal tip of the
pseudostratified dorsal epithelium of the neural tube, giving rise to most cells of
the peripheral nervous system forming neurons and glial cells, bones and
craniofacial cartilage cells of the skeletal system, endocrine system derivatives
for the adrenal and thyroid glands, adipose tissue, vascular smooth muscle
tissues as well as mesenchymal dermal cells and melanocytes 227,228.
During neurulation, the NCCs undergo EMT whereby they separate from
the neural tube and begin to stereotypically migrate extensively 229–231. As the
NCC migrate they are subjected to an interplay of signals including BMP,
NOTCH, WNT and FGF from the non-neural ectoderm and mesoderm that not
only aids in their migration but also helps determine their cell fate 228,232,233.
Neural crest cells that migrate dorsolaterally become melanoblasts, progenitor
cells for melanocytes 227. Melanoblast specification and differentiation depends
on a complex system of signaling pathways including WNT, BMP, and EDN3.
Proper melanoblast development does not take place in the absence of any of
these signals 21,234,235. Melanoblasts eventually migrate into the ectoderm where
they become melanocytes and produce the pigment melanin.
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Melanomas may be intrinsically prone to metastasize because of their
EMT transformation and high migratory capability associated with their
developmental program 236–239. Bailey and colleagues (2012) transplanted
aggressive human melanoma cells (c8161), poorly invasive human melanoma
cells (c81-61) and human primary melanocytes into a chick embryonic NCC
environment 237. Laser capture microdissection and genetic analysis techniques
were used to compare the gene and signaling pathways exploited by the c8161,
c81-61 and primary melanocytes 237. They reported that the malignant
melanoma cells, c8161, responded more vigorously to the NCC environmental
cues than the poorly invasive melanoma cells and primary melanocytes,
indicating that receptors for NCC development were present and active in the
c8161 cells 237. The c8161 cells also commandeered the embryonic NCC
invasion program to enhance their own invasiveness and plasticity 237. A number
of c8161 cells responded to the NCC microenvironment and migrated along
NCC migration routes from the graft sites, while none of the non-invasive and
primary melanocytes migrated 237. The expression patterns of migrating c8161
cells did not exactly mirror that of the NCC suggesting that the tumor cells can
manipulate the NCC development program to suit their own agenda 237.
Furthermore 40% of the analyzed NC-related genes were induced by the
aggressive cell line compared to only 8% induction in the poorly invasive cells.
The invasive cells also re-expressed approximately 12 NC-related genes not
seen in the primary melanocytes such as SNAI1, ZEB1 and members of the Eph
family and silenced others involved in differentiation237.
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Because of the dynamic regulation of both stemness and a highly complex
microenvironment it is important to identify and fully characterize potential
biomarkers for melanoma to improve diagnosis and treatment. One such target
that has been implicated is EDNRB and its ligand EDN3.
1.5.

Melanoma and Endothelin Signaling
Endothelins (EDN) are twenty one amino acid (aa) peptides that act as

powerful vasoconstrictors and vasodilators 240–242. Preproendothelin transcription
yields the 203aa prepro-endothelins which are further modified by furin-like
proteases to produce 37-41aa big-EDN intermediates which are biologically
inactive. The big-EDNs are finally cleaved by membrane bound zinc
metalloproteases known as endothelin converting enzymes (ECE) at the Trp-21Val/lle-22 peptide bond to form the active peptides EDN1, Endothelin 2 (EDN2)
and EDN3 240–247. The EDN1 protein is produced by vascular endothelial and
smooth muscle tissue, as well as fibroblasts, cardiac myocytes and brain
neurons, with EDN2 mainly secreted by ovaries and intestinal cells and Edn3 by
endothelial cells, vascular smooth muscle cells, brain neurons, intestinal
epithelial cells, hepatocytes and adventitial fibroblasts 241,242,248.
In humans, the EDNs bind to two different rhodopsin-type G-protein
coupled receptors (GPCRs), Endothelin receptor A (EDNRA) and EDNRB with
different affinities. Endothelin 1 and Endothelin 2 preferably bind to EDNRA,
however EDNRB is non-selective and binds all three peptides with similar affinity
240,249

. Binding of EDN1 activates the heterotrimeric G proteins G q /G 11 and

G 12 /G 13 while EDN3 triggers G i /G o and G 13 to activate phospholipase Cβ and
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signal through several different pathways including PKC and MAPK 249–254.
Endothelin receptor A and Endothelin receptor B can form homodimers or
heterodimers which modifies not only ligand binding but receptor activation, and
transmembrane signaling as well 250.
The structure, function and importance of the EDNRA/EDN1 axis in
vasoconstriction, proliferation of melanocytes and as a melanogenic factor have
been extensively characterized, however not as much is known about the role of
the EDNRB/Edn3 axis. The human EDNRB gene is situated on chromosome 13,
and has seven exons and introns. Approximately 64% of its sequence homology
is shared with EDNRA 242. Found mostly in ECs, EDNRB facilitates the release of
NO and prostacycline, acting mainly as a vasodilator as opposed to EDNRA’s
vasoconstrictor effects in response to Ca2+ influx that results from stress on ECs
during cardiovascular stress or hypoxia 248,255,256. Endothein receptor B and
EDN3 have a profound effect on melanocyte development and have been
recently identified as a potential relevant factor in melanomagenesis.
Waardenburg syndrome IV is associated with mutations in EDNRB and
EDN3 that disrupt proper development of enteric nerves and melanocytes
resulting in hearing loss, skin, eye, and hair color abnormalities as well as
blockage of the intestines known as Hirschsprung disease 257–259. Targeted
mutations of EDNRB and EDN3 in mice results in similar phenotypes such as
aganglionic megacolon and pigmentation defects which corroborate the
necessity for EDNRB and EDN3 signaling in proper melanoblast
development 260–263,264.
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Lee and colleagues (2003) used the tetracycline inducible system to
control EDNRB expression to reveal that EDNRB is required during E10.5-E12
for melanoblast migration and proliferation 265. Hou and colleagues (2004) used
tissue re-combination experiments ‘in vitro’ with NCC cultures and mouse
embryos carrying a EDNRB null allele with the LacZ reporter gene to further
show that EDNRB is required for melanoblast differentiation as it is needed for
melanoblasts to express the melanogenic enzyme tyrosinase 265. Endothelin
receptor B acts in an autocrine manner as mammalian melanoblasts themselves
begin to express EDNRB along the mediolateral pathway 265–267, while the
indispensable role of EDN3 is believed to act in a paracrine fashion as EDN3 is
expressed by the dermal mesenchyme and the ectoderm 265,268.
Studies carried out with avian NCCs show that EDN3 acts as a potent
mitogen for both melanoblasts and differentiated melanocytes and promotes
melanoblast proliferation and survival 269–271. Absence of EDNRB and EDN3 in
murine and avian NC cultures give rise to melanoblasts that are unable to
differentiate properly as they lack the melanogenic markers involved in pigment
production such as tyrosinase 272 or simply cannot produce pigment unless
stimulated with EDNs 273. Interestingly however, exposure of epidermal
melanocytes to a strong treatment of EDN3 ‘in vitro’ could stimulate the
proliferation of not only pigmented melanocytes but a population of cells coexpressing melanin and glial markers and unpigmented cells expressing glial
markers or early NC cell markers 271. Thus continuous exposure of EDN3 can
initiate transdifferentiation of differentiated melanocytes and maintain the
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multipotent progeny 271. The influence EDN3 has on melanocyte dedifferentiation
may be important during melanomagenesis however more studies are needed to
examine this relationship.
Endothelin receptor B signaling has been implicated as a melanoma
progression marker. Although studies such as Kikuchi et al. (1996) and Eberle et
al. (1999) communicated that EDNRB expression decreased in more malignant
melanoma cell lines they examined, other studies such as that conducted by
Bittner et al (2000) and Demunter et. al (2000) examining more melanoma cell
lines found that ENDRB expression was instead upregulated 274–277. Lahav and
colleagues (1999) further explored the effect of ENDRB on melanoma
progression ‘in vitro’ and ‘in vivo’. The ‘in vitro’ experiments showed that
exposure of 7 different melanoma cell cultures to the EDNRB antagonist BQ788,
could inhibit cell growth and induce dendricity and increase pigmentation of the
cells, thus conferring a phenotype more similar to mature melanocytes than
melanoma cells 278. When the A375 melanoma cell line was injected into nude
mice, the resulting tumors were subjected to BQ788, after which the tumors
showed either slowed tumor growth or slowed tumor growth with tumor shrinkage
and complete growth arrest 278. Later Lahav and colleagues (2004) used human
melanoma cell lines from various stages of melanoma progression to support
that EDNRB may be important in melanoma progression. Inhibition of EDNRB
using BQ788 in the melanoma cell lines induced apoptosis and decreased cell
viability of the metastatic melanoma cell lines more than that found in primary
and cutaneous cell lines 279. The inhibition of EDNRB may possibly trigger
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apoptosis because of decreased expression of the survival factor, BCL-2A1and
the PARP-3 enzyme which is aids in DNA repair 279. Inhibition of the EDNRB axis
both ‘in vivo’ and ‘in vitro’ in other studies likewise found reduction of melanoma
growth 280.
Endothelin 3 activation of EDNRB may be the key factor in EDNRB
mediated effects on melanoma growth as Nengxing et al. (2007) showed ‘in vitro’
that EDN3 prompted increased proliferation of A375 melanoma cells in a time
and concentration dependent manner 281. Cruz-Muñoz and colleagues (2012)
used lentiviral vectors to upregulate EDNRB in stable variant human melanoma
cell line models that spontaneously develop visceral metastasis (113/6-4L) and
brain metastasis (131/4-5B1 and 131/4-5B2) 282. Increased levels of EDNRB in
both the visceral and brain metastatic cell lines boosted their metastatic potential
leading to shorter median survival in those with the visceral metastasis and an
increased number of brain metastases in the brain metastatic variant 282. CruzMuñoz and colleagues (2012) identified EDN3, which is also highly expressed in
the brain microenvironment, to be the major factor in the EDNRB mediated
enhanced brain metastatic events 282.
Tang and colleagues (2008) gene expression profiling analysis comparing
normal nevi biopsies to metastatic tissues identified abnormal expression of
EDN3 in melanoma 283. Quantitative PCR analysis showed an up-regulation over
10 fold of EDN3 in the metastatic melanoma biopsies than normal nevi
biopsies 283. Melanoma specific EDN3 immunohistochemistry (IHC) staining was
also observed only in the metastatic tissues 283. Six out of seven melanoma cell
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lines, examined by Tang and his associates (2012), showed EDN3 expression
while normal melanocyte cultures did not. Their data suggest that not only is the
EDNRB/EDN3 axis involved in melanoma but also that the melanoma cells
themselves may be the source of EDN3 283.
The EDNRB/EDN3 axis may aid in melanoma progression by
influencing mechanisms in the tumor microenvironment. Bagnato and colleagues
(2004), Rosanò and colleagues (2004) and Jamal and colleagues (2002) used
melanoma cell lines exposed to EDN1 and EDN3 to show that after treatment,
the cell lines had decreased E-cadherin levels 148,284,285. Bagnato and colleagues
(2004) also showed a concomitant upregulation of N-cadherin and that mRNA of
the EMT transcription factor, Snail, that negatively controls E-cadherin
expression was observed in the primary melanoma cell line thus suggesting a
potential role for EDNs in EMT 280. Exposure of primary cell line (1007) and
metastatic melanoma cell line (M10) to EDN1 and EDN3 resulted in the
increased secretion of ECM proteases MMP-2 and MMP-9 and the integrins
α 2 β1 and α v β 3 all important players in the tumor microenvironment 280.
The association of endothelins with endothelial cells, makes the
EDNRB/EDN3 axis worth examining for any prospective roles in tumor
angiogenesis. Endothelins are often secreted at sites of wounds or injured
vessels 286. Endothelin 1 and Endothelin 3 can stimulate production of NO and
stimulate migration of endothelial cells 287, in addition, they are expressed by
endothelial cells of lymphatic vessels, which is also important in cancer
metastasis 288. Spinella and colleagues (2007) research on primary melanoma
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(1007) and metastatic melanoma (M10) cell lines conveyed that both EDN1 and
EDN3 could increase Hif-1α mediated upregulation of VEGF and angiogenic
factors, COX-1, COX-2 and PGE 2 in a concentration dependent manner 289. The
expression of COX-2, Hif-1α, VEGF and MMP-2 were also decreased in M10
tumor bearing mice in response to EDNRB inhibition with A-19262 289. Zbytec
and colleagues (2013) used bioinformatics to also identify putative hypoxia
response elements (HRE’s) in EDNRB 209. Spinella and colleagues (2013) further
revealed that EDNRB/EDN1 axis could induce VEGF-3 signaling to activate
MAPK and AKT to promote cell migration and vasculogenic mimicry of primary
and metastatic melanoma cell lines 290. Wren and colleagues (1993) showed that
EDN3 could specifically support wound healing by stimulating endothelial cell
proliferation without activation of either EDNRA or EDNRB in an ‘in vitro’
endothelial cell injury model, thus potentially calling into question other mediated
mechanisms of EDN3 signaling 291.
Conversely, previous studies by Lahav and colleagues inferred negative
effects of EDNRB on melanoma angiogenesis 279. When they inhibited EDNRB in
melanoma cell lines, microarray and real time RT-PCR analysis disclosed
significant increased levels of VEGF and Hif-1α along with decreased levels of
the angiogenic suppressor gravin 279. A majority of the studies examining the
relationship between the EDNRB axis and melanoma have been performed
using ‘in vitro’ methods. However, it is well known that melanoma cells behave
very differently in culture from when they are situated in their tumor
microenvironment where they are affected by the induced changes in the host. It
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is therefore important to examine the effects of EDNRB/EDN3 in an ‘in vivo’
model.
Mayuko and colleagues (2010) used a RET mouse model that form
melanomas de novo (do not arise from pre-existing benign lesions) to study the
status of EDNRB in melanoma progression 292. They found a negative correlation
between levels of EDNRB with tumor progression. Transgenic Ednrb(+/−);RET
mice acquired their tumors significantly later but metastasized earlier and had
shorter survival ratios when compared to Ednrb(+/+); RET mice 292. Kumasaka
and colleagues (2015) later described that the enhanced malignant phenotype in
the Ednrb(+/−);RET mice was the result of reduced levels of Plexin C1 (PlxnC1)
a protein normally involved in melanocyte adhesion that has been labeled as a
melanoma suppressor protein 293.
Still, studies such as Soufir and colleagues (2005) who explored whether
germline mutations in EDNRB associated with Hirschsprung disease could
predispose individuals for malignant melanoma, found that fourteen out of fifteen
malignant melanoma (MM) patients had EDNRB mutations found in
Hirschsprung disease 294. When the variables such as skin type and number of
nevi were considered by multivariable logistic regression analysis, they still found
a significant relationship between mutations in EDNRB and MM incidence 294.
Moreover, both ‘in vitro’ and clinical trials using the EDNRB antagonist bosentan
to treat melanoma cell lines 295 and metastatic melanomas in patients 296 aided in
apoptosis of melanoma cells and may have stabilization effects of metastatic
disease 295–297.
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1.6.

Research Questions
Seemingly contradictory influences of the EDNRB/EDN3 axis on

melanoma could be attributable to the use of ‘in vitro’ methods that expose the
cells to unnatural and stressful tissue culture conditions as well as the lack of an
‘in vivo’ model that closely parallels melanoma progression in humans. Much is
still unknown about the exact role played by EDNRB/EDN3 signaling in
melanomagenesis. My overall hypothesis is that EDNRB/EDN3 signaling acts in
a paracrine manner to promote melanoma growth and metastasis. I tested this
hypothesis by asking three major questions.
Question 1: Is the up-regulation of the Endothelin 3/Ednrb signaling pathway
sufficient to lead hyperproliferative melanocytic lesions to fully malignant metastasis?

Studies on the role that EDN3 plays in melanoma progression have mainly
been conducted using melanoma biopsies and cells from different stages of
melanoma progression. Although this has been instrumental in identifying EDN3
upregulation in more malignant melanoma stages, it is still not clear whether
EDN3 signaling is a driving force in actual melanoma malignancy. In order to
address this question in vivo I established a melanoma mouse model by crossing
Tg (Grm1) Epv mice that aberrantly express metabotropic glutamate 1 (Grm1)
exclusively in melanocytes under the regulation of the Dopachrome tautomerase
promoter with K5-tTA-Edn3 (here referred to as K5-Edn3) transgenic mice that
over-express Edn3 in the skin or Tg(Ednrb)1Lk (here referred to as Dct-Ednrb)
transgenic mice that over-express Ednrb in melanocytes. The Tg (Grm1) Epv
mice develop melanocytic hyperplasia with limited metastatic capability 298,299. I
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hypothesize that the presence of more Edn3 in the tumor microenvironment or
Ednrb in melanocytes of the Tg (Grm1) Epv mice will lead hyperproliferative
melanocytic lesions to fully malignant metastasis and contribute to melanoma
progression.
Question 2: What are the gene expression changes caused by the overexpression of Edn3 in the tumor microenvironment?
During embryogenesis, Ednrb and Edn3 are involved in proper
melanoblast development and migration. Melanoma cells share specific
characteristics with melanoblasts that allow them to be malignant. These
characteristics include high proliferative capabilities, a lack of differentiation and
reduced intercellular adhesion. I hypothesize that the over-expression of Edn3 in
the tumor microenvironment in the K5-Edn3/ Tg (Grm1) Epv mice will alter gene
expression of adhesion factors such as cadherins, integrins, and connexins and
those involved in differentiation and proliferation such as Mitf and HGF that have
been shown to occur ‘in vitro’ during melanoma progression.
Question 3: Is the Edn3 pathway involved in promoting changes in the tumor
microenvironment that enhances melanoma malignancy?

Metastasis is a multistep process involving neighboring cells in the tumor
microenvironment being reprogrammed by tumorigenic cells to express factors
that aid in the tumor’s survival, proliferation, immune escape and invasiveness.
The angiogenic cascade is affected by multiple factors in the tumor microenvironment
including tumor hypoxic conditions, and a host of bi-directional signaling among tumor
and neighboring cells. Thus in order to investigate the true role of EDNRB/EDN3 in
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angiogenesis, it is best to do so in an ‘in vivo’ model where the Edn3 axis can affect its
specific targets or be influenced by other complement of factors that may be needed for it
to mediate its effects. I hypothesize that the over-expression of Edn3 will have a
significant effect in melanoma angiogenic response.
1.7.
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1.8.

Figure Legends

Figure 1 Cutaneous melanoma may arise from precursor lesions, either a benign
nevus or a dysplastic nevus. It is also believed that melanoma can develop
directly from abnormal stem cells and not from an existing nevus. Melanomas
can then progress to the radial growth phase characterized by proliferation of
tumorigenic cells and invasion limited only to the epidermis. The vertical growth
phase can then follow, in which the tumorigenic cells begin to grow vertically and
invade the deeper tissue of the dermis. Once the melanoma invades the dermis,
the tumorigenic cells and can enter into the lymphatic or circulatory system to
colonize other organs leading to the metastatic phase of the skin cancer.
Figure 2 The tumor microenvironment includes various cells that have been
recruited and inducted by tumorigenic cells such as carcinoma associated
fibroblasts, immune cells such as neutrophils, macrophages and lymphocytes,
cells that contribute to neovascularization such as endothelial cells and the
modified extracellular matrix termed the ‘reactive stroma’. (A) The different cells
in the tumor microenvironment are influenced by factors secreted by the
tumorigenic cells, and in turn produce factors that contribute to the development,
growth, invasion and metastasis of melanoma (B).
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Figure 1 Melanoma Progression.

Figure 2 Melanoma Tumor Microenvironment.
A

B
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II.

2.1.

ENDOTHELIN SIGNALING PROMOTES TUMOR PROGRESSION AND
METASTASIS IN A MOUSE MODEL OF MELANOMA
Introduction
Tumors are comprised not only of transformed malignant cells but also of

a complex system of stroma and various other cell types. This niche is commonly
referred to as the ‘tumor microenvironment’, and each part is integral in
promoting malignancy and metastasis 1, 2. Melanoma results from the initial
transformation of epithelial melanocytes and subsequent alteration in the
associated stroma. Melanoma lesions encompass cells such as fibroblasts,
keratinocytes, endothelial and immune cells, all of which inherit dysfunctional
cytokine pathways that facilitate malignancy. The tumorigenic cells acquire the
ability to reprogram the normal functions of these neighboring cells in the tumor
microenvironment, and establish a number of paracrine and autocrine signaling
loops to promote angiogenesis, epithelial to mesenchymal transformation and
metastasis. The exact mechanisms of the signaling loops are not yet fully
understood, but many of them are regulated by growth factors and G-protein
coupled receptors (GPCRs) 3-5.
G Protein Coupled Receptors can become tumorigenic either by acquiring
intrinsic mutations that make the receptors constitutively active or by being
exposed to excessive amounts of their ligands 5-7. Endothelin receptor b
(EDNRB) is a GPCR that has been implicated in melanoma progression.
Endothelin receptor B ligands, endothelins 1, 2, and 3 (EDN1, 2, 3) are primarily
involved in vascularization, by acting as vasoconstrictors and vasodilators,
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promoting endothelial cell survival and migration as well as in the mitogenesis of
endothelial cells, vascular smooth muscle cells, fibroblasts, and pericytes 8, 9.
Additionally, during embryonic development EDNRB and EDN3 are critical for
melanocyte proliferation and survival. Endothelin receptor B has also been
implicated in melanocyte differentiation before the cells migrate into the
epidermis, while EDN3 may be able to delay the differentiation of the
melanocytes 10. Mice carrying mutations of either Ednrb or Edn3 exhibit
pigmentation defects such as those seen in the spontaneous mouse mutants
piebald lethal and lethal spotting, respectively 11-13.
In vitro studies using melanoma cell lines, along with gene expression
analysis and immunohistochemistry on melanoma biopsies have found that
Ednrb expression is progressively up-regulated from dysplastic nevi to metastatic
melanomas 14-17. Tang and colleagues found that EDN3 was up-regulated more
than 10-fold at the mRNA level in metastatic melanoma biopsies when compared
to benign nevi, while EDN1 and EDN2 expression remained low. They also
showed that six out of seven cultured melanoma cell lines expressed EDN3 while
human epidermal melanocytes did not 18.
Treatment of melanoma cell lines with the EDNRB antagonist BQ788
resulted in decreased cell viability by inhibiting proliferation 14, 19 and sensitivity to
the inhibitor was more intense in the metastatic malignant cells 20. The antagonist
BQ788 also induced signs of differentiation such as increased dendricity and
pigmentation of cultured melanoma cells as well as reduced tumor growth in
nude mice implanted with melanoma cell grafts 14. Other in vitro studies suggest
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that EDN3 may be relevant to specific tumor-host interactions, as treatment of
melanoma cell lines with EDN1 and EDN3 resulted in decreased levels of the cell
adhesion molecule E-cadherin and increased levels of N-cadherin, which allow
the tumorigenic cells to interact with other cell types such as fibroblasts and
endothelial cells 21.
The purpose of our study was to develop melanoma metastasis mouse
models to characterize the EDN3/EDNRB axis in melanoma progression and the
tumor-host relationships it is involved in to promote metastasis. Transgenic mice
that present with spontaneous melanocytic lesions in regions such as the ears
and tails with limited metastatic capability (Tg(Grm1)Epv (E) 22-24) were crossed
to transgenic mice that over-express EDN3 by keratinocytes (K5-tTA;TRE-Edn3lacZ 25), transgenic mice that over-express EDNRB in melanocytes
(Tg(Ednrb)1Lk), or both. The over-expression of Edn3 in the skin
microenvironment or of Ednrb in melanocytes led to the formation of rapidly
growing highly metastatic lesions allowing for the direct evaluation of the role
played by EDN3 in the process of melanomagenesis in vivo.
2.2.

Materials and Methods

2.2.1. Mice and Genotyping
The K5-tTA;TRE-Edn3-lacZ (K5-Edn3 used here for simplicity) and
Tg(Ednrb)1Lk mice (Dct-Ednrb used here for simplicity), which were generated in
our laboratory 25 , were crossed with the Tg(Grm1)Epv (E) mice (Dct-Grm1used
here for simplicity, a gift from Dr. William Pavan, NIH) 22. Briefly, the K5-Edn3
mice (C57BL/6XSJL/FVB/N) were generated using the tetracycline regulatory
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inducible system and harbors the tTA activator in the regulatory region of the Bos
Taurus gene for Keratin 5 to drive the constitutively active expression of End3.
The Dct-Ednrb transgenic mice were generated by microinjection of a transgene
containing the full length Ednrb cDNA (1958bp, genbank accession # U32329)
under the regulation of 3431 bp of the mouse Dct promoter and the BGH poly
adenylation signal into FVB F 1 zygotes. The founder line was propagated
subsequently for over 10 generations by crosses with C57BL/6J mice. Dct-Grm1
transgenic mice express the metabotropic glutamate receptor 1 under the
regulation of the melanocyte specific Dopachrome tautomerase promoter.
Deoxyribonucleic acid (DNA) from tail biopsies were extracted using
standard techniques from the progeny of the Dct-Grm1, K5-Edn3, and Dct-Ednrb
matings, and Polymerase Chain Reaction (PCR) was used to genotype the mice
using the following primers: Dct-Grm1 5’-CCGGGTCCGCATTAATCTTATCTA3’and 5’-GGTAGCATACGGTTCCACGCA-3’ which yield a 1700bp PCR product;
the K5-tTA primers 5’-CCAGGTGGAGTCACAGGATT-3’ and 5’ACAGAGACTGTGGACCACCC-3’and the primers for the tetO-Edn3 yield a 463
bp product and bind to the 3’ end of the Edn3 cDNA (5’GGCCTGTGCACACTTCTGT-3’) and to non-coding DNA (5’TCCTTGTGAAACTGGAGCCT-3’); Dct-Ednrb 5’ACAAGGAAGACTGGCGAGAA-3’ and 5’-TCCTCCCCCTTGCTGTCCTGC-3’
which produce a 2218 bp fragment flanking the Dct promoter. Mice were housed
in the University Animal Care Facility at Florida International University. The
animal protocol was approved by the Committee on Animal Care and Use and
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Office of Sponsored Research at Florida International University and all
Institutional Animal Care and Use Committee regulations were followed.
2.2.2. Tumor Measurements
After the genotypes of the mice were determined at approximately four
weeks of age, mice from the experimental Dct-Grm1/K5-Edn3 and Dct-Grm1/DctEdnrb, and control (Dct-Grm1/ K5, Dct-Grm1/ Edn3 and Dct-Grm1) groups were
monitored on a weekly basis for tumor development. The time of tumor
appearance for each mouse was calculated as the time between the date of birth
of the mouse and the date of the appearance of the first raised melanocytic
lesion. The data was plotted as a Kaplan-Meier graph using the Statistical
Package for the Social Sciences (SPSS) program Version 13.0 and a log rank
test was used for statistical analysis.
Tumor growth of the experimental mice and their control counterparts
were measured weekly for 16 weeks using calipers to calculate tumor volume
using the equation: length X breadth2 X 0.5 14. Student’s t-test was used for the
statistical comparisons. Differences were considered statistically significant at
p<0.05.
2.2.3. Metastasis Analysis
At approximately 9-12 months of age, tumor burdened mice were
examined for the presence of metastases in the lymph nodes as well as other
common sites of melanoma metastasis such as the lungs and brain. Lymph
nodes and organs considered to contain metastatic lesions were fixed overnight
in 4% paraformaldehyde in phosphate buffered solution (PBS, pH 7.4), subjected
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to 10% sucrose (in PBS, pH 7.4) for six hours, followed by 20% sucrose (in PBS,
pH 7.4) overnight and finally embedded in OCT medium (Ted-Pella, CA) and
stored at -80°C. Samples were sectioned and processed for
immunofluorescence.
2.2.4. Immunofluorescence
For the analysis of proliferating tumor cells, cryosections (10µm thick) of
tail tumors at three different stages of tumor development were obtained. The
stages were classified as: Stage 1- when the tumor became a raised lesion at
approximately 0.5mm in height, Stage 2- at approximately 25-30mm3, and Stage
3- after the tumor developed for 9-12 months. The sections were bleached
overnight in 10% hydrogen peroxide in PBS (pH 7.4) in order to decolorize
melanin. After bleaching, the sections were washed with PBS (pH 7.4) three
times for 15 minutes and then blocked for 1 hour and 15 minutes in a solution of
10% Goat Serum (Gibco), 0.1% Triton X-100 (Sigma, MO) in PBS (pH 7.4). For
immunolabeling, the sections were incubated overnight at 4°C with Anti Ki-67
polyclonal antibody (1:100, Abcam, MA), for one hour with secondary antibody
Alexa Flour 488 Goat Anti-Rabbit (1:200, Invitrogen, NY) and counterstained with
Hoechst. The Ki-67 positive cells were counted in 10 different sections, 5 fields of
view each section, per tumor, using Image J and shown as a percentage of the
total number of cells identified by Hoechst.
To confirm the presence of metastatic lesions in lymph nodes and visceral
organs, cryosections (10µm thick) were labeled with antibodies against the
melanoma marker S-100 (1:200, Dako, CA) and the melanocyte marker Trp1
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(1:200, polyclonal rabbit antibody Pep1 provided by Vincent Hearing, NIH). The
secondary antibody used was Alexa Flour 488 Goat Anti-Rabbit (1:200,
Invitrogen, NY) and the sections were counterstained with propidium iodide.
Images were obtained and analyzed with a Leitz DMRB fluorescent microscope
and photographed with a Leica DC 500 camera.
2.2.5. Real-time RT-PCR
RNA was extracted from tail tumors at stages 1, 2, and 3 of tumor
development (n=5 for each stage). The RNA extraction and purification were
conducted using TRIzol Reagent (Invitrogen, NY), the RNeasy Mini Kit (Qiagen,
CA) and RNase Free DNase Set (Qiagen, CA). The RNA quality and quantity
were assessed using absorbance readings at 260nm, 280nm and 230nm with
the Nano Drop (ND-1000) spectrophotometer. First strand cDNA synthesis of
RNA was performed using the Maxima Reverse Transcriptase Kit (Fermentas,
MA).
Semiquantitative analysis of transcripts encoding α v , α 2, β 1, ß 3 , VEGF-A,
VEGF-B, Hif-1α, N-cadherin, E-Cadherin, EDNRB, MITF , MCAM, Galectin 3,
and GAPDH was conducted by real-time Polymerase Chain Reaction using the
Applied Biosystems 7300 Real-Time PCR System. All primer sequences are
listed in Table 1 of the Supplementary Data. The real-time PCR reaction was
performed in triplicates with SYBR Green I dye, for a total volume of 26µl per
reaction which included 1µl of cDNA, and 0.44µM of each primer and 12.5µl of
Maxima® SYBR Green/ROX qPCR Master Mix (Fermentas, MA). ‘No template’
controls were also used in the real time experiments. The threshold cycle (Ct)
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values quantified for the target transcripts and the housekeeping gene, Gapdh,
were used to derive the fold change for each transcript between the DctGrm1/K5-Edn3 experimental group and Dct-Grm1 controls.
2.3.

Results

2.3.1. Edn3 Promotes Early and Rapid Melanoma Growth
The Dct-Grm1 mice acquire melanocytic lesions that mature into overt
melanomas on the tails and ears as a result of the aberrant glutamate signaling.
However, the spontaneous acquired melanomas do not give rise to metastatic
lesions in distant organs 22. The melanoma mouse model was therefore a
suitable candidate to assess a putative role for EDN3 in tumor progression and
metastasis. The Dct-Grm1 mice were crossed with the K5-Edn3 mice to generate
an experimental population of transgenic Dct-Grm1/ K5-Edn3 animals as well as
a population of control counterparts that lack the over-expression of EDN3 (DctGrm1, Dct-Grm1/K5, Dct-Grm1/Edn3). The K5-Edn3 mice produce higher levels
of Edn3 in the skin starting at around embryonic day 12.5 that persist into
adulthood. The elevated levels of EDN3 lead to an increase in the number of
melanocyte precursors and their maintenance in the adult skin resulting in a
hyperpigmentation phenotype 25. The experimental Dct-Grm1/K5-Edn3 mice
(n=25) and the control mice (Dct-Grm1, Dct-Grm1/K5, Dct-Grm1/Edn3) (n=25)
were monitored weekly to observe differences in tumor development between the
two groups. The time it took for the first melanocytic lesion to develop on the
mice was calculated from the date of birth of the mice to the date when the first
tumor appeared. The data plotted on a Kaplan Meier graph, revealed that the
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Dct-Grm1/K5-Edn3 mice acquired their first melanocytic lesion significantly
earlier (p<0.001) than the Dct-Grm1 control mice (Fig.1A). The Dct-Grm1/K5Edn3 mice acquired their first tumor on average at about 23 weeks after birth,
while the average time for the Dct-Grm1 control mice to acquire their first tumor
was at approximately 31 weeks after birth.
Once present, the tumors of the Dct-Grm1/K5-Edn3 mice grew faster than
the Dct-Grm1 tumors. Ear tumors grew 13 times faster in the experimental mice
(n=20) than in the control mice (n=20) (p=1.3864E-06). The size of the tumors at
each week was also significantly different between experimental and control
groups (p ≤ 0.009) (Fig. 1B-D). The tail tumors of the Dct-Grm1/K5-Edn3 mice
grew 5 times faster than those of the Dct-Grm1 mice. Over the 16 week period,
the size of the Dct-Grm1/K5-Edn3 tail tumors (n=20) were significantly larger
(p=0.004) than the controls (n=20) (Supplementary Fig. S1).
In order to determine the underlying mechanism for the difference in tumor
growth between the control and experimental animals, we counted the number of
proliferating tumorigenic cells by labeling the lesions at Stages 1 and 2 with an
antibody against Ki-67 (Fig. 2A-L). At both stages the Dct-Grm1/K5-Edn3 mice
had a higher percentage of Ki-67 positive cells than the Dct-Grm1 controls (Fig.
2M, N), but the difference was only significantly greater for the Dct-Grm1/ K5Edn3 group at Stage 2 (p=0.01).
2.3.2. Edn3 Promotes the Formation of Dorsal Skin Tumors
Apart from the ear and tail tumors Dct-Grm1/K5-Edn3 transgenic mice
also acquired pigmented melanocytic lesions on their dorsal skin (Supplementary
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Fig. S2), a condition not observed or previously described in the Dct-Grm1
control mice. The dorsal skin lesions were observed in 75% of the Dct-Grm1/K5Edn3 mice (n=40) and could be detected as early as 12 weeks after the mice
were born. Like the ear and tail tumors, the dorsal lesions first appeared as nonraised skin lesions and continued to form large overt tumors on the skin. The
dorsal lesions stained positive for S100 and Trp1, thus confirming these lesions
were of melanocytic origin and were spontaneous melanomas similar to the tail
and ear tumors.
2.3.3. Edn3 Promotes Melanoma Metastasis to Lymph Nodes and Visceral
Organs
The Dct-Grm1/K5-Edn3 and the Dct-Grm1 control mice were examined for
signs of metastasis after the first melanocytic tumor had been present for
approximately 6.5 to 9 months. Eight-one percent of the Dct-Grm1/K5-Edn3
(n=37) mice presented with metastases in lymph nodes and distant organs while
none of the Dct-Grm1 control counterparts (n=35) did. The Dct-Grm1 mice
showed micrometastases, on average two per lung (n=3), but the areas where
they were found were not labeled with antibodies against Trp-1 and S100. All
experimental animals showed enlarged highly pigmented lymph nodes. Although
some control animals also displayed enlarged lymph nodes, they never stained
positive for Trp1 indicating the absence of cells of melanocytic origin
(Supplementary Fig. 3A-F). The lymph nodes of the Dct-Grm1/K5-Edn3 were
significantly larger (p≤ 0.001) than those of the Dct-Grm1 control mice
(Supplementary Fig. 3G). The most common site where secondary lesions were
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observed was the lungs (23/37) (Fig.3A-B). The lungs’ pigmented lesions ranged
from large overt metastatic tumors, smaller pigmented lesions that were clearly
visible with the naked eye, to much smaller micrometastases that were only
visible under a dissecting microscope. These lesions labeled positive for Trp1
and S100 confirming their melanoma nature (Figure 3C). The brain was the
second most common site for melanoma metastasis (14/37) (Fig. 3D-F).
Metastatic lesions were also found in the salivary glands (9/37), spleen (2/37)
and kidney (1/37) of the Dct-Grm1/ K5-Edn3 mice. The lesions found in these
organs were also positive for S100 or Trp1 (n=5). The Dct-Grm1/K5-Edn3 mice
often had metastatic lesions in multiple organs concomitantly, for example, in the
brain and lungs (Supplementary Table 2).
2.3.4. Edn3 Alters the Expression of Genes Involved in Metastasis
Because the Dct-Grm1/K5-Edn3 mice had a more aggressive metastatic
phenotype than the Dct-Grm1 controls we assessed for differences in the
expression of genes implicated in melanoma metastasis that included cell
adhesion and cell-matrix interaction proteins, angiogenic factors, and relevant
melanocytic developmental genes. At Stage 1 there was significant upregulation of α v, α 2 , β 3 integrin subunits, VEGF-A, both E-cadherin and Ncadherin as well as Galectin 3 in the Dct-Grm1/ K5-Edn3 tumors when compared
to the controls (Fig. 4A). At Stage 2, only VEGF-B and Hif-1α were significantly
up-regulated in the experimental tail tumors (Fig. 4B), while at Stage 3 the
expression levels of N-cadherin, E-cadherin, Galectin 3, Mitf and MCAM were
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found to be significantly higher in the Dct-Grm1/ K5-Edn3 mice than the control
group (Fig. 4C).
2.3.5. EDNRB Promotes Early and Rapid Melanoma Growth, and Strong
Metastatic Properties
Since we did not observe much up-regulation of Ednrb in the lesions of
Dct-Grm1/ K5-Edn3 in comparison to those of control Dct-Grm1 animals we
investigated if forced Ednrb over-expression in melanocytes under the Dct
promoter would also alter the dynamics of tumor growth and the metastatic
potential of the tumorigenic cells. The Dct-Grm1 mice were crossed with the DctEdnrb mice to generate an experimental population of transgenic Dct-Grm1/ DctEdnrb animals as well as a population of control counterparts that lack the overexpression of Ednrb (Dct-Grm1). As for the Dct-Grm1/K5-Edn3 mice, Dct-Grm1/
Dct-Ednrb acquired their first melanocytic lesion significantly earlier (p=0.004)
than the Dct-Grm1 control mice (Fig.5A). The Dct-Grm1/Dct-Ednrb mice acquired
their first tumor on average at about 26 weeks after birth, while the average time
for the Dct-Grm1 control mice to acquire their first tumor was at approximately 45
weeks after birth. The tumors of the Dct-Grm1/Dct-Ednrb mice grew faster than
the Dct-Grm1 tumors. Ear tumors grew 70 times faster in the experimental mice
(n=11) than in the control mice (n=7) (p=3.365E-05). The size of the tumors at
each week (except for week 1, 2 and 4) was also significantly different between
experimental and control groups (p ≤ 0.04) (Fig. 5B). The tail tumors of the DctGrm1/Dct-Ednrb mice grew 22 times faster than those of the Dct-Grm1 mice.
Over the 16 week period, the size of the Dct-Grm1/Dct-Ednrb tail tumors (n=15)
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were significantly larger (p=0.001) than the controls (n=10) (Supplementary Fig.
S4). Seventy six percent (n=25) of Dct-Grm1/Dct-Ednrb mice presented with
metastasis by 1 year of age. Interestingly, the percentage of Dct-Grm1/Dct-Ednrb
animals that had metastasis in the brain (60%, Supplementary Fig. S5) was
almost double that of Dct-Grm1/ K5-Edn3 animals (37%).
We also generated a small number of animals over-expressing both Edn3
and Ednrb by crossing Dct-Grm1/K5-Edn3 with Dct-Grm1/Dct-Ednrb animals.
Dct-Grm1/K5-Edn3/Dct-Ednrb mice (n=19) acquired their first melanocytic lesion
significantly earlier than the Dct-Grm1-K5-Edn3 (n=16; p=0.001) and DctGrm1/Dct-Ednrb (n=4; p=0.006) mice (Supplementary Fig. S6). The DctGrm1/K5-Edn3/Dct-Ednrb mice acquired their first tumor on average at about 13
weeks after birth, while the average time for the Dct-Grm1/K5-Edn3 mice to
acquire their first tumor was at 22 weeks and for the Dct-Grm1/Dct-Ednrb was at
24 weeks after birth. All Dct-Grm1/K5-Edn3/Dct-Ednrb animals had metastasis in
the lungs by 1 year of age. These results clearly demonstrate that the upregulation of the Edn3/Ednrb signaling pathway in melanocytes accelerates the
process of melanomagenesis and stimulates malignancy.
2.4.

Discussion
In this study we created novel metastasis melanoma mouse models in

order to evaluate the role of the Ednrb /Edn3 axis in melanoma progression. The
Dct-Grm1/ K5-Edn3 mouse model showed that excessive Edn3 paracrine
signaling from keratinocytes affects melanoma progression and metastasis.
There have been very few genetically engineered mouse models of melanoma
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with visceral metastasis reported 26. To our knowledge, the Dct-Grm1/ K5-Edn3
is the first spontaneous metastasis melanoma mouse model that is dependent on
the presence of a signaling molecule exclusively in the tumor microenvironment.
The Dct-Grm1/ Dct-Ednrb model further supports a role for the endothelin
signaling pathway in melanoma progression and corroborates recent findings
that over-expression of Ednrb may be an important factor driving melanoma brain
metastases27.
Previous studies using melanoma cell lines showed that inhibition of
Ednrb resulted in the decrease of tumor growth 14, 21, 28. Thus, EDN3 may be one
of the critical mitogenic factors directly affecting melanoma growth as its upregulation in the Dct-Grm1/ K5-Edn3 mouse not only significantly shortened the
length of time it took for the development of melanocytic lesions but also
increased how fast both ear and tail tumors grew. Comparative
immunofluorescence analysis of Ki-67 using two different stages of melanoma
development also showed significantly higher amounts of proliferating cells in the
tail tumors of the Dct-Grm1/ K5-Edn3 mice. Thus, in vivo over-expression of
End3 alters melanoma progression kinetics leading to an increase in growth rate.
Since endothelins are known to participate in angiogenesis, the effect of EDN3 in
melanoma growth rate may be due to an increase in neovascularization that is
necessary to provide the tumor with adequate supplies of nutrients and oxygen in
order to survive and grow past 2mm 29.
Endothelin receptor B has been closely associated with the melanoma
metastatic phenotype. Endothelin receptor B gene expression is higher in
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metastatic melanoma cell lines and biopsies in comparison to nevi and primary
melanomas 17, 20, 30. It was suggested that Edn1 was the primary ligand acting on
EDNRB to promote melanoma progression while EDN3 was not as vital since it
was not found to be up-regulated by ultraviolet light

17, 31, 32

. Notwithstanding,

Tang and colleagues (2008) found that EDN3, and not EDN1, was significantly
up-regulated more than 10 fold in metastatic melanoma biopsies when compared
to benign nevi and promoted melanoma cell survival 18. Additionally, EDN3 was
required along with other growth factors and ultraviolet light to transform human
melanocytes into melanoma in vivo 33. Combined with our results, these findings
show that the presence of Edn3 in the tumor microenvironment contributes to
melanoma progression.
To further characterize the effects of EDN3 on melanoma metastasis we
examined whether its presence would enhance melanoma malignancy in the DctGrm1/ K5-Edn3 mouse model when compared to the Dct-Grm1 mice that have
limited metastatic capability. It was recently reported that the Dct-Grm1 mice
have pigmented Grm1/Dct positive disseminated cells in the lymph nodes and
non-pigmented Dct positive cells in the lung and liver 24. Nevertheless, the DctGrm1/K5-Edn3 mice have a considerable more aggressive melanoma phenotype
than the Dct-Grm1 control mice. Thus, EDN3 in the tumor microenvironment
must lead to cellular and molecular changes required for the metastatic process.
The occurrence of distant metastases in the Dct-Grm1/Dct-Ednrb mice, albeit
with smaller penetrance when compared to the Dct-Grm1/K5-Edn3 animals,
indicates that the levels of ligand available in the skin and/or lesions is not
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limiting for the changes required to enhance the metastatic potential of the
tumorigenic cells.
Gene expression analysis of Dct-Grm1/K5-Edn3 tail tumor development
indicated that changes were stage specific and that the metastatic process was
occurring as early as the lesions were noticeable. One of the most surprising
findings was that the expression levels of cadherins, in any of the stages
examined did not follow the E-cadherin to N-cadherin switch that has been widely
accepted as a key component in melanomagenesis 34-36. Except for the 2-3mm
stage where E-cadherin was slightly down-regulated and N-cadherin was slightly
up-regulated, both cadherins showed similar expression levels in the other two
stages. One possible explanation for the failure to detect the cadherin switch is
that we compared gene expression levels between two types of tumors and not
between normal and transformed melanocytes where the switch normally occurs.
Another possible explanation is that unlike human skin, mouse melanocytes are
not found in the epidermis but reside primarily in hair follicles. Even though the
melanocytes in the Dct-Grm1/K5-Edn3 mice are localized around the epidermaldermal junction, they may not be under the same type of control from the
keratinocytes. Therefore E-cadherin levels may not need to be drastically
reduced in these tumors.
The potential role of Edn3 in tumor angiogenesis is supported by the
expression changes in VEGF-A, VEGF-B and Hif-1α. The observed up-regulation
of VEGF-A in tumors at Stage 1 suggests its involvement in the recruitment,
proliferation, and differentiation of endothelial cells that are important to the tumor
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microenvironment 37. More striking is the fact that the only two genes upregulated at Stage 2, when the Dct-Grm1/ K5-Edn3 tail tumors begin to grow
faster than those in the Dct-Grm1 controls, were VEGF-B and Hif-1α. These
results corroborate previous studies that showed that Edn1 and Edn3 up-regulate
the expression of VEGF and Hif-1α 38, 39.
The changes in the expression of cell-matrix and cell adhesion molecules
such as integrin α v , β 3 and α 2 subunits as well as Galectin 3 in Dct-Grm1/ K5Edn3 lesions at stage 1 suggest that the tumorigenic cells gain migratory and
metastatic properties very early in tumor development. The up-regulation of
integrin β 3 subunit is normally used to characterize the melanoma vertical growth
phase (VGP), is found on 80% of VGP’s, 100% of metastatic melanomas 40, and
correlates to the presence of lung metastases. Both the α v β 3 subunits and
Galectin 3 function as receptors for elastins and elastin-derived peptides that
have been shown to promote tumor progression and metastasis 41. Galectin 3
was also up-regulated at stage 3 along with MCAM, when melanoma lesions in
distant organs were detected indicating that Edn3 may exert its effects
throughout the metastatic process. A previous study showed that the silencing of
Galectin 3 in metastatic melanoma cells in nude mice significantly decreased the
number of lung metastases 42. Melanoma cell adhesion molecule gene
expression progressively increases during melanoma progression until it is at its
highest in metastatic melanoma cells 43-45, and MCAM aids in the later stages of
metastasis including extravasation and establishing new foci of growth 46.
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The other gene found to be up–regulated at stage 3 was the transcription
factor Mitf. This result is in accordance with some but not all expression studies
performed with human biopsies and cell lines. Microphthalmia associated
transcription factor (MITF) was sometimes found to be highly expressed in
benign nevi, and either absent or expressed at high levels in metastatic
melanomas 47-49. The expression of MITF in melanoma specimens has been
inversely correlated to that of Hif1-α and the induction of Hif1-α in melanoma cell
lines led to a decrease in the levels of MITF 50 . We observed the same
relationship at all stages examined: when the expression of Hif1-α was high, Mitf
levels were very low (stages 1 and 2) and vice-versa (stage 3).
Together, our findings show that increased signaling via Ednrb, either by
higher levels of the receptor on melanocytes or the ligand in the
microenvironment, promotes a more malignant melanoma phenotype, and can
stimulate tumor growth and metastasis. The Dct-Grm1/ K5-Edn3 and DctGrm1/Dct-Ednrb melanoma mouse models can be employed to further our
understanding of changes that lead to melanoma progression and test strategies
to prevent these changes in order to inhibit metastasis.
2.5.
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2.6.

Figure Legends

Figure 1 Time to tumor appearance and tumor growth rate in Dct-Grm1/K5-Edn3
mice. (A) Kaplan–Meier curve of tumor-free survival. The tumor free-survival
period of Dct-Grm1/K5-Edn3 mice (n= 25) was significantly shorter (p=0.001, logrank test) than that of Dct-Grm1 controls (n=25). (B-C) Dct-Grm1 and DctGrm1/K5-Edn3 mice with same age ear tumors (arrows). (D) Weekly tumor size
of Dct-Grm1/K5-Edn3 (n=20) ear tumors is significantly larger (p= 1.3864E-06, Ttest) than that of Dct-Grm1 controls (n=20) Error bars, s.e.m. The sizes of the
Dct-Grm1/K5-Edn3 and Dct-Grm1 control group ear tumors were significantly
different at each week (*p ≤ 0.009, T-test).
Figure 2 Proliferation analysis of Dct-Grm1/K5-Edn3 mouse tumors. (A-L)
Representative sections of Dct-Grm1/K5-Edn3 and Dct-Grm1 tail tumors at
Stage 1 and 2 labeled with Ki-67 antibody (green) and counterstained with
Hoescht (blue). Scale bar: 50 µm. (M and N) Quantification of the ratio of Ki-67
positive cells to total number of cells (n=5). The number of Ki-67 positive cells
was significantly higher (*p= 0.01) in the Dct-Grm1/K5-Edn3 tumors when
compared to those of Dct-Grm1 controls only at Stage 2.
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Figure 3 Metastatic lesions in Dct-Grm1/K5-Edn3 mice. Metastases in lung (A)
and brain (D). Scale bar: 2mm. Cryosections (10µm) of lung (B, C) and brain (E,
F) metastases stained with Hematoxilin and Eosin (B, E) and labeled with Trp1
antibody (C, F). Scale bar: 2mm (A, D) 50µm (B, C, E, F).

Figure 4 Gene expression analysis of Dct-Grm1/K5-Edn3 mouse tumors. Semiquantitative real time RT-PCR analysis comparing tail tumors taken at three
different stages of tumor progression from Dct-Grm1/K5-Edn3 and Dct-Grm1
controls. Expression levels determined to be significant when equal or larger than
2 fold.
Figure 5 Time to tumor appearance and tumor growth rate in Dct-Grm1/DctEdnrb mice. (A) Kaplan–Meier curve of tumor-free survival. The tumor freesurvival period of Dct-Grm1/Dct-Ednrb mice (n= 18) was significantly shorter
(p=0.004, log-rank test) than that of Dct-Grm1controls (n=18). (B) Weekly tumor
size of Dct-Grm1/Dct-Ednrb (n=11) ear tumors is significantly larger (p= 3.365E05, T-test) than that of Dct-Grm1 controls (n=7) Error bars, s.e.m. The sizes of
the Dct-Grm1/Dct-Ednrb and Dct-Grm1 control group ear tumors were
significantly different at each week (*p ≤ 0.04, T-test) except for week 1, 2 and 4.
Supplementary Figure 1 Tail tumor growth rate in Dct-Grm1/K5-Edn3 mice.
Weekly tumor size of Dct-Grm1/K5-Edn3 (n=20) tail tumors is significantly faster
(p= 0.004, T-test) than that of Dct-Grm1 controls (n=20) Error bars, s.e.m. The
sizes of the Dct-Grm1/K5-Edn3 and Dct-Grm1 control group tail tumors were
significantly different at each week (*p ≤ 0.02, T-test).
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Supplementary Figure 2 Dorsal tumors in Dct-Grm1/K5-Edn3 mice. DctGrm1/K5-Edn3 mice (n=30) developed tumors on the dorsal skin (A) that stained
positive for the S100 melanoma marker (B). Scale bar: 50µm.
Supplementary Figure 3 Lymph node metastasis. (A-F) Representative
sections of cervical lymph nodes labeled with Trp1 antibody (green). Scale bar:
50µm. (G) Dct-Grm1/K5-Edn3 cervical (n= 8; *p= 8.99493E-06, T-test) and
inguinal lymph nodes (n= 6; **p= 1.14E-04, T-test) were significantly larger than
those of Dct-Grm1 controls. Error bars, s.e.m.
Supplementary Figure 4 Tail tumor growth rate in Dct-Grm1/Dct-Ednrb mice.
Weekly tumor size of Dct-Grm1/K5-Edn3 (n=15) tail tumors is significantly faster
(p= 0.001, T-test) than that of Dct-Grm1 controls (n=10) Error bars, s.e.m. The
sizes of the Dct-Grm1/Dct-Ednrb and Dct-Grm1 control group tail tumors were
significantly different at each week except for week 1(*p ≤ 0.01, T-test).
Supplementary Figure 5 Brain metastatic lesions in Dct-Grm1/Dct-Ednrb mice.
(A) Metastases in the brain (arrows). (B) Hematoxilin and Eosin stained
cryosection (10µm) brain. Scale bar: 2mm (A) 50µm (B).
Supplementary Figure 6 Time to tumor appearance in Dct-Grm1/K5-Edn3/DctEdnrb mice. Kaplan–Meier curve of tumor-free survival. The tumor free-survival
period of Dct-Grm1/K5-Edn3/Dct-Ednrb mice (n=19) was significantly shorter
than that of Dct-Grm1/K5-Edn3 (n=16) and Dct-Grm1/Dct-Ednrb (n=4) mice
(p=0.001 and p=0.006, respectively; log-rank test).
Supplementary Table 1: Location of metastases found in Dct-Grm1/K5-Edn3
mice.
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Supplementary Table 2: Primers used for Real Time PCR gene expression
analysis
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Figure 1 Time to tumor appearance and tumor growth rate in Dct-Grm1/K5-Edn3 mice.
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Figure 2 Proliferation analysis of Dct-Grm1/K5-Edn3 mouse tumors.

104

Figure 3 Metastatic lesions in Dct-Grm1/K5-Edn3 mice.
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Figure 4 Gene expression analysis of Dct-Grm1/K5-Edn3 mouse tumors.

Supplementary Figure 1 Tail tumor growth rate in Dct-Grm1/K5-Edn3
mice.

Supplementary Figure 2 Dorsal tumors in Dct-Grm1/K5-Edn3 mice.
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Supplementary Figure 3 Lymph node metastasis.
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Supplementary Figure 4 Tail tumor growth rate in Dct-Grm1/Dct-Ednrb
mice.

Supplementary Figure 5 Brain metastatic lesions in Dct-Grm1/Dct-Ednrb
mice.
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Supplementary Figure 6 Time to tumor appearance in
Dct-Grm1/K5-Edn3/Dct-Ednrb mice.
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Supplementary Table 1 Location of metastases in Dct-Grm1/K5-Edn3 mice.
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Supplementary Table 2 Primers used for Real-time PCR gene expression analysis.

CHAPTER III
ENDOTHELIN 3 ENHACES TUMOR ANGIOGENESIS IN AN EDN3
DEPENDENT MELANOMA MOUSE MODEL

112

III. ENDOTHELIN 3 ENHANCES TUMOR ANGIOGENESIS IN AN EDN3
DEPENDENT MELANOMA MOUSE MODEL
3.1.

INTRODUCTION
Angiogenesis is a critical step triggered in response to hypoxic conditions,

by the tumorigenic cells in melanoma malignancy 1–4. The process encompasses
the formation of new blood vasculature from pre-existing vessels located in close
proximity to the tumors. The new vasculature can surround as well as enroot
inside tumors, providing it with nutrients and oxygen to promote survival, growth
and metastasis 5–7. The melanoma cells initiate the tumor ‘angiogenic switch’
disrupting the balance between pro-angiogenic and anti-angiogenic factors, by
secreting a number of pro-angiogenic factors such as vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth
factor (PDGF) and transforming growth factors α and β (TGFα and TGFβ) 8–11.
These pro-angiogenic factors stimulate the proliferation, migration and survival of
endothelial cells. Endothelial cells can then in turn secrete a number of autocrine
and paracrine growth factors along with the tumor to recruit and activate
pericytes, inflammatory cells and remodel the extracellular matrix to allow blood
vessel formation 8–11. One of the growth factors linked to angiogenesis in
melanoma is Endothelin receptor B (EDNRB), a seven transmembrane G-protein
coupled receptor 12,13.
Endothelin receptor b binds its three ligands endothelins 1, 2, 3 (EDN1,
EDN2 and EDN3) with equal affinity 14,15. Endothelins are important in
melanocyte differentiation and survival as well as in endothelial localization and
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vasoconstriction of blood vessels 16–18. During melanomagenesis, EDNRB
expression increases in malignant melanomas when compared to melanocytic
nevi. Furthermore both ‘in vivo’ and ‘in vitro’ experiments blocking EDNRB with
its antagonist BQ788 restricted melanoma growth and induced apoptosis of the
tumorigenic cells 17,19,20. Spinella and colleagues (2007) using both primary
(1007) and metastatic (M10) cell lines of melanoma showed binding of EDN1 and
EDN3 to EDNRB could enhance both VEGF, Hif-1α transcript levels and
increase cyclooxygenase (COX)-1/COX-2 protein expression, COX-2 promoter
activity and prostaglandin E2 (PGE2), all factors important in angiogenesis 21.
Although the EDNRB/EDN1 axis has been implicated in melanoma, little is
known about the effect of the upregulation of EDN3 in the tumor
microenvironment in melanoma progression. Tang and colleagues found that
EDN3 was upregulated at both the mRNA and protein level almost 10 fold in
malignant melanomas, while the other two ligands EDN1 and EDN2 did not show
much change 22. In Chapter 2 I described a novel EDN3 dependent melanoma
mouse model, Dct-Grm1- /K5-Edn3 mice, whose overexpression of EDN3
actuated melanocytic lesions with limited metastatic capability to a more
aggressive form. The Dct-Grm1/K5-Edn3 are hyperpigmented mice that
constitutively overexpress Edn3 under the Keratin 5 promoter and have aberrant
expression of metabotropic glutatamate receptor 1 (Grm1) under the
Dopachrome tautomerase promoter. Real time RT-PCR studies on the
melanocytic tumors of the Dct-Grm1/K5-Edn3 mice revealed a significant fold
increase in angiogenic related genes Vegf, Hif-1α and integrins α v β 1 and α 2 β 3 at
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different stages of tumor progression when compared to the Dct-Grm1 control
group that do not overexpress EDN3. In this chapter I further examined the
effects EDN3 plays in the angiogenic switch and tumor neovascularization, that
may be contributing to the more characteristic aggressive phenotype of
melanoma observed in the Dct-Grm1/K5-Edn3 mice.
3.2.

MATERIALS AND METHODS

3.2.1. Animal Model
The Tg(Grm1)Epv/K5-Edn3 mice generated in our laboratory were crossed and
genotyped. Deoxyribonucleic acid (DNA) from tail biopsies were extracted using
standard techniques from the albino progeny of the matings, and Polymerase
Chain Reaction (PCR) was used to genotype the mice using the following
primers: Dct-Grm1 5’-CCGGGTCCGCATTAATCTTATCTA-3’and 5’GGTAGCATACGGTTCCACGCA-3’ which yields a 1700bp PCR product; the K5tTA primers 5’-CCAGGTGGAGTCACAGGATT-3’ and 5’ACAGAGACTGTGGACCACCC-3’and the primers for the tet-O Edn3 yield a 463
bp product and bind to the 3’ end of the Edn3 cDNA (5’GGCCTGTGCACACTTCTGT-3’) and to non-coding DNA (5’TCCTTGTGAAACTGGAGCCT-3’). The mice were housed in the University
Animal Care Facility at Florida International University. The animal protocol was
approved by the Committee on Animal Care and Use and Office of Sponsored
Research at Florida International University and all Institutional Animal Care and
Use Committee regulations were followed.
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3.2.2. Immunofluorescence
Primary tail tumors (25-30mm3) from Dct-Grm1/K5-Edn3 mice (n=5) and
Dct-Grm1 control mice (n=5) were excised, fixed and embedded in OCT medium
(Ted-Pella, CA) following the protocol previously described in Chapter 2.
Cryosections (10µm thick) of the tail tumors were later decolorized of melanin by
incubating overnight in 10% hydrogen peroxide in 1X PBS (pH 7.4). Ten sections
from each tumor were immunolabeled with either the antibody Anti-CD31
(Abcam, MA) (1:50), an endothelial cell marker to visualize and quantify the
vascular network of the tumor. Positive staining was identified with the secondary
antibody Alexa Flour 488 Goat Anti-Rabbit antibody (Invitrogen, NY) (1:200) and
the sections were counterstained with propidium iodide. A Leica Leitz DMRB
florescent microscope and a Leica DC 500 camera was utilized to observe and
take pictures of five fields of view at 200X of each of the ten sections for both the
Dct-Grm1/K5-Edn3 mice and the Dct-Grm1 controls samples. The area of staining
was analyzed using the pixel density feature of ImageJ software and compared
between the experimental and control population using the Student T-test.
3.2.3. Angiogenesis Array
Proteome profiling using the ‘Multianalyte Profiling Angiogenesis Kit’ from R&D
Systems (R&D Systems, MN) was used to analyze the relative expression of 53 mouse
angiogenesis related proteins in tail tumors of Dct-Grm1/K5-Edn3 experimental mice
and their corresponding Dct-Grm1 controls (Dct-Grm1, Dct-Grm1/K5, DctGrm1/Edn3). Primary tail tumors (25-30mm3) were excised from Dct-Grm1/K5Edn3 mice (n=4) and Dct-Grm1 controls (n=4) and homogenized in PBS with
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protease inhibitors aprotinin (Sigma, MO), leupeptin (Sigma, MO), and Pepstatin
(Sigma, MO). Protein was extracted from each of the samples and
concentrations were quantified using the ‘BCA Protein Assay Kit’ (Thermo
Scientific). Nitrocellulose membranes spotted with both control and capture
antibodies for the mouse angiogenic proteins were incubated overnight, after
which the membranes were washed. Streptavidin-HRP and chemiluminescent
reagents were then used to detect the signal produced at each spot
corresponding to the amount of bound protein, and the array data was developed
onto an X-ray film for analysis using the Protein Array Analyzer program in Image
J. Student’s t-test was used for the statistical comparisons. Differences were
considered statistically significant at P<0.05.
3.3.

RESULTS

3.3.1. Edn3 Overexpression Increases the Vascular Density in Melanocytic
Tumors
Tail tumor cryosections showed significantly (p= 0.044) higher levels of Anti-CD31
(Abcam, MA) staining in the Dct-Grm1/K5-Edn3 mice (n=5) when compared to the
Dct-Grm1mice (n=5) (Fig.1).
3.3.2. Edn3 Overexpression Affects the Levels of Expression of Angiogenic
Proteins.
The Multianalyte Profiling Angiogenesis Kit’ from R&D Systems (R&D Systems,
MN) allowed for the parallel observation of the relative levels of 53 different mouse
angiogenic proteins (Fig. 2) involved with neovascularization. When I compared protein
extracts from primary tail tumors (25-30mm3) of both Dct-Grm1/K5-Edn3 mice (n=4)
and Dct-Grm1 control mice (n=4), I found (p≤0.05) that the expression of the angiogenic

117

proteins Endoglin, Heparin-binding Epidermal growth factor (HB-EGF), Matrix
metalloproteinase-9 (MMP-9), Angiogenin, Insulin-like growth factor-binding
protein 2 and 3 (IGFBP-2 and IGFBP-3), CCN intercellular signaling protein 3
(CCN3), Edn-1 and Chemokine (C-X-C motif) ligand 16 (CXCL16) in the DctGrm1/K5-Edn3 tumors was significantly higher than in the controls (Fig. 3).
3.4.

DISCUSSION
During angiogenesis, endothelial cells are recruited by tumorigenic cells,

whereby they dissever their normal cell-cell adhesions, migrate, proliferate, and
form new cellular attachments to establish neovascularization. Platelet
endothelial cell adhesion molecule (PECAM-1), also known as ‘cluster of
differentiation 31’ (CD31) is a member of the Immunoglobin family that comprises
most of endothelial intercellular junctions. The Dct-Grm1/K5-Edn3 primary tail
tumors showed significantly more CD31 immunofluorescence staining than primary tail
tumors with the same average tumor volume of the Dct-Grm1 control group. Greater
levels of CD31 staining in the Dct-Grm1/K5-Edn3 primary tail tumors suggest a
greater degree of vascularization within tumors exposed to high levels of EDN3
in the tumor microenvironment. Endothelin signaling via EDNRB is reported as
having direct effects on endothelial cell proliferation and neovascularization by
enhancing Hif-1α mediated events 13,21. It would be interesting to evaluate and
compare the levels of hypoxia in the tail tumors of the Dct-Grm1/K5-Edn3 mice and
the Dct-Grm1 control mice as tumorigenic cells found close to hypoxic regions have
been observed to become more aggressive and metastatic 23.
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The results obtained from the analysis of Dct-Grm1/K5-Edn3 mice suggest
one mechanism by which EDN3 in the tumor microenvironment increases melanoma
malignancy. We profiled the expression of 53 mouse angiogenic related proteins and
also found a significant increase in several angiogenic related factors, including MMP-9
and nephroblastoma overexpressed (NOV/CCN3) protein. Matrix metalloproteinases
(MMP’s), proteases are responsible for degrading and remodeling the ECM while
matricellular proteins such as galectins, thrombospondin, osteopontin and
nephroblastoma overexpressed (NOV/CCN) proteins regulate cell-matrix interaction as
well as proliferation, differentiation and survival of particular cell types 24. Both groups
cooperate to facilitate the recruitment of cells involved in the neoangiogenic process as
well as altering the migration of tumorigenic cells. Matrix metallopeptidase -9 along with
Matrix metalloproteinase -2 are main degraders of collagen Type IV which comprises
majority of basement membrane ECM 2526. Matrix metallopeptidase -9 activity has been
connected to melanomagenesis. Microarray gene chip analysis comparing cell lines of
highly aggressive and poorly aggressive forms of melanoma performed by Seftor and
colleagues (2001) found significant upregulation of MMP-9 27. Shellman and colleagues
examined active secretions of normal melanocytes and cell lines of different melanoma
stages using zymography techniques. They too positively correlated an increase in active
MMP-9 secretions with malignancy. Matrix metallopeptidase -9 was only detected in the
vertical growth phase and metastatic melanoma cell lines 28. Matrix metallopeptidase -9
has also been associated with vascular mimicry in melanoma. Vascular mimicry is a
process first described by Mantois et al. 1999, whereby tumorigenic cells of highly
metastatic melanomas are able to form their own acellular microcirculatory channels,
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founded of ECM and tumorigenic cells 29. The vasculature does not include endothelial
cells, instead mimic the neoangiogenic vessels formed during tumor angiogenesis. The
vascular mimics connect to the host microcirculatory system and supply the tumor with
nutrient rich oxygenated blood and a metastatic route 29,30. Vascular mimicry is often
linked to poor prognosis in melanoma patients 31. When both endothelial cellular and
vascular mimicry vessel number were decreased ‘in vivo’, MMP-9 gene and protein
expression was also reduced, suggesting a role for MMP-9 in vascular mimicry and a
more metastatic phenotype 31–34.
Studies on the role of matricellular protein CCN3 with respect to
melanoma have been somewhat contradictory. CCN3 encoded by the NOV gene
belongs to a family of ECM associated growth and differentiation regulators. NOV
mediates its effects by binding to receptors such as integrin receptors and
NOTCH 35,36. In one study, gene and protein expression analysis revealed that
co-culturing melanocytes with keratinocytes led to an increase of CCN3 levels,
melanocyte proliferation was inhibited, as well as correct spatial localization of
the melanocytes to the basement membrane was disrupted 37. Melanocytes
transduced with siRNA knocking down CCN3 showed decrease in their growth
rates and attachment to Collagen IV when compared to cells transduced with
control vectors. Later experiments using immunohistochemical analysis on
different stages of melanoma progression found lower CCN3 expression levels in
advanced melanomas. The ‘1205Lu’ melanoma cell line overexpressing CCN3
became less proliferative and invasive on 3D skin reconstructs. However, no
difference was observed in migration assays in the absence of Matrigel between
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CCN3 overexpressing cells and controls. Matrix metalloproteinase -2 and matrix
metallopeptidase -9 expression levels were also decreased in CCN3
overexpressing cells 38. These results suggest an inverse relationship between
CCN3 expression and melanoma progression.
Vallachi and colleagues (2008) however presented a positive function for
CCN3 in fostering melanoma progression. A cDNA library constructed from
primary and metastatic melanoma cell lines from the same patient was analyzed
with Northern analysis and RT-PCR. Higher expression levels of CCN3 were
found in the metastatic melanomas when compared to primary tumor cells 39.
The CCN3 protein expression was also higher in a large panel of visceral and
nodal melanoma metastases of patients with short term survival or relapse
patients compared to those patients with long term survival 39,40.
Immunocompromised mice transfected with melanoma cells expressing CCN3
further showed more visceral metastatic growth 39,40.
Several studies have established that the functions of CCN3 are
dependent on the cellular and tissue context 24,37,41. CCN3 is linked to prostate
cancer progression 42, tumor differentiation in cartilage tumors 43 and yet has an
anti-proliferative function in gliomas 44. It is not surprising therefore that CCN3
activity in melanoma may be very complex depending on the stage of disease
progression. The tumor microenvironment is also a very important facet when
trying to characterize the importance or exact mechanism by which a particular
factor might be involved in, especially one like CCN3 whose role has been
inconsistent. In the ‘in vivo’ EDN3 dependent metastatic melanoma Dct-Grm1/K5-
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Edn3 mouse model CCN3 was upregulated at the same stage when Hif-1α, MMP-9,
and angiogenic related genes linked to melanoma such as angiogenin 45 and endoglin
46,47

. The angiogenic protein array also detected the upregulation of several Insulin-like

growth factor binding proteins (IGFBPs). IGFPs are major regulators of the NOV family
39,40

. In the presence of EDN3 in the tumor microenvironment CCN3 may be elevated to

enhance angiogenesis and malignancy in melanoma.
The heparin binding CXC chemokines are factors involved in inflammation
and immunity that have also emerged as agents in tumorigenic angiogenesis for
a number of cancers including melanoma 48. The significance of CXCL 16, the
ligand for the receptor CXCR6, has not yet been studied in melanoma or its
relationship with endothelins. More research should be done to elucidate the
importance of this molecule in melanoma progression.
Angiogenesis is a critical process in tumor survival and metastasis.
Although it has been explored as a target of many cancer therapeutics 49, the
tumor microenvironment along with the complexity of its mechanisms, that seem
to vary depending on the type of cancer, diminishes or abolishes the
effectiveness of treatments. A study conducted by Lahav and colleagues (2004)
contradicts our findings, having reported that EDNRB signaling may have a
negative effect on tumor angiogenesis as inhibition of EDNRB increased VEGF
expression and suppressed angiogenic inhibitor Gravin 50. The different results
may be because Lahav and colleagues’ study (2004) utilized human melanoma
cell lines treated with the EDNRB antagonist BQ788 in culture, which differs from
our methods that used an ‘in vivo’ melanoma model that also encompasses
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changes EDN3 has on the tumor microenvironment and its subsequent effects
on the tumorigenic cells. Melanocytic tumors in the Dct-Grm1/K5-Edn3
melanoma mouse model tumors grow faster and display increased metastatic
capability, hence EDN3 may be either directly or indirectly augmenting
angiogenic related factors needed to not only increase vascularization but
increase the metastatic capability of the melanocytic tumors in these mice when
compared to the controls. Blocking EDN3 in the tumor microenviroement or
EDNRB expression in the tumorigenic cells may decrease the angiogenic
response in melanoma and help prevent the metastatic process. Thus the DctGrm1/K5-Edn3 melanoma mouse model that has metastatic primary tumors with
a strong angiogenic tumor response is a very useful tool to elucidate further the
role EDNRB/EDN3 signaling plays in melanoma angiogenesis.
3.5.
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3.6.

Figure Legends

Figure 1 Immunofluorescence detection of Anti-CD31. 10µm sections of tail
tumors (25-30mm3) from Dct-Grm1/K5-Edn3 (A) and Dct-Grm1 control
counterparts (B) were stained for the endothelial cell marker CD-31 and
counterstained using propidium iodide. Image J pixel density analysis and the
Students T-test determined that Dct-Grm1/K5-Edn3 tail tumors had significantly
more Anti-CD31 staining (p= 0.044) than the Dct-Grm1 control tail tumors (C).
Scale bar 50µm. (A, B).
Figure 3 Example of a labeled array demonstrating different levels of protein
expression.
Figure 2 Proteome profiling of mouse angiogenic related proteins. Proteome profiling
was used to analyze the relative expression of 53 mouse angiogenesis related proteins in
primary tail tumors (25-30mm3) of Dct-Grm1/K5-Edn3 experimental mice and their
corresponding Dct-Grm1 controls. Dct-Grm1/K5-Edn3 mice had significantly
(p≤0.05) more expression of angiogenic proteins Endoglin, HB-EGF, MMP-9,
Angiogenin, IGFBP-2, IGFBP-3, CCN3, Edn-1 and CXCL16.
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Figure 1 Analysis of tumor vascular density in Dct-Grm1/K5-Edn3 mice.
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Figure 3 Proteome profiling of mouse angiogenic related proteins.
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IV. CONCLUSIONS, FUTURE DIRECTIONS AND IMPLICATIONS
4.1.

Conclusions and Future Directions
This study provided evidence that upregulation of EDN3 in the tumor

microenvironment or EDNRB in transformed melanocytes can affect tumor
behavior leading to a more aggressive melanoma phenotype as well as alter
expression of genes involved in cell adhesion, and the tumor angiogenic
response.
In this study the over-expression of EDN3 in the skin was present prior to
tumor formation and throughout its development. In order to further understand
the relevance of EDN3 in tumor progression and evaluate the potential of
targeting this pathway during the course of human disease, it will be important to
identify the exact timing the effect of EDN3 is most critical. It will also be
interesting to establish if the role EDN3 plays in tumor growth can be separated
from that of its role in promoting metastasis. These questions can be addressed
in the future utilizing the tetracycline inducible system in the K5-Edn3 mouse
model. EDN3 signaling can be switched off at different time points during
melanoma tumor progression in Dct-Grm1/ K5-Edn3 mice to determine when
tumor appearance, growth and spread can be stopped.
My results showed that EDN3 affected the angiogenic response of
melanoma by changing gene expression and an increase in the amount of tumor
vascularization. Many cancer regimens focus on targeting tumor angiogenesis
and tumor vasculature, a vital component in tumor survival, growth and
metastasis. Anti-angiogenic therapies include targeting either factors involved in

132

angiogenesis such as VEGF or attempting to normalize the tumor vasculature.
Some anti-cancer regimens are not effective because treatment cannot always
be delivered to the entire tumor via its blood supply as irregular leaky vessels,
associated with tumors, often do not reach all parts of the tumor1. The
inadequate blood supply maintains hypoxic regions within the tumor and
cancerous cells that can escape therapeutics. Often cancer patients may also
exhibit anti-VEGF resistance. The mechanisms responsible for triggering
resistance, and whether or not this is tumor type dependent within types of
cancers has not been established.
Results from the proteome profiling array analysis showed that VEGF-β is
expressed more than VEGF in the tumors (25-30 mm3) of the Dct-Grm1/ K5-Edn3
mice. We will investigate whether inhibition of both VEGF receptors (VEGFR-1 and
VEGFR-2) using polyclonal IgG neutralizing antibodies to VEGFR-1 (R&D Systems;
AF471) and VEGFR-2 (R&D Systems; AF471) at different tumor stages can
significantly reduce tumor size, growth rate and prevent metastasis in the tumors of the
Dct-Grm1/ K5-Edn3 mice. These experiments will help us learn more about the
importance of VEGF and potential VEGF therapeutics in melanoma treatment.
The tumors of Dct-Grm1/ K5-Edn3 mice are an ideal system to evaluate
the efficacy of novel non-invasive tools to measure blood flow and levels of
oxygenation that may be used in patients to determine the status of certain types
of cancer. For example, I have started to collaborate with a group from the
Department of Biomedical Engineering at Florida International University to use
diffuse reflectance spectroscopy and a novel spectral interpretation algorithm 2,3
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to analyze and compare regions of hemoglobin oxygenation in tail tumors of the
Dct-Grm1/ K5-Edn3 mice.
4.2.

Implications

Although enlightening, studies on EDNRB in melanoma progression and
metastasis were mostly conducted ‘in vitro’ using cell lines or in ‘pseudomelanoma mouse models’. Therefore ‘pro-tumor’ effects of EDNRB are still
incompletely characterized and more studies should be conducted in an ‘in vivo’
model to fully understand the mechanisms involved in order to develop and test
effective preclinical therapeutic regimes against melanoma metastasis. The Dct-Grm1/
K5-Edn3 mouse model provides an ‘in vivo’ EDN3 dependent visceral metastatic
melanoma model that does not require forced oncogene activation and in which
EDN3 expression can be controlled using the tetracycline inducible system to
examine melanomagenesis at various stages of progression associated with its
tumor microenvironment. As a consequence of the nature of the K5-Edn3 mice,
the Dct-Grm1/ K5-Edn3 mouse model has an increased number of melanocytes
in the epidermal-dermal junction in the skin which more closely resembles the
human skin phenotype which makes the model a prime candidate for
investigating melanoma progression and correlating the findings to those found in
humans 4.
The highly aggressive nature of melanoma renders it one of the most
formidable cancers to treat. Some melanoma tumors less than 2mm in thickness
have been diagnosed with metastatic potential, making it increasingly important
to understand the molecular and genetic mechanisms of melanoma metastasis.
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There are few mouse melanoma models that demonstrate such a robust
metastatic phenotype as our Dct-Grm1/ K5-Edn3 mouse model that can provide
a valuable tool in understanding metastatic progression using ‘in vivo’ methods,
as the microenvironment is indispensable when trying to fully elucidate
metastasis. Park and colleagues (2011) using cross-species hybridization of
microarray experiments to characterize the influence of the microenvironment on
tumor cell behavior, showed that when melanoma cell line A375SM were
xenografted into mouse brain organ sites, they acquired characteristics of
neuronal lineage cells and began to express genes related to neurological
signaling such as Synaptosomal-Associated Protein 21 (SNAP21),
Synaptosomal-Associated Protein 91 (SNAP91) and Bassoon Presynaptic
Cytomatrix Protein (BSN) 5. These genes were not overexpressed by the
A375SM cells when they were xenografted into other metastatic sites. Thus
melanoma cells may not only adopt a more undifferentiated cell type, but may
also undergo transdifferentiation due to epigenetic and transcriptome
reprogramming to adopt similar characteristics of cells at the metastatic sites 5.
This process may explain the strong chemoresistance of melanoma cells. The
Dct-Grm1/K5-Edn3 metastatic melanoma mouse model may therefore be an
important tool for testing potential drug therapeutics.
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